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Abstract 
Glioblastoma Multiforme (GBM), a glioma – cancer of the brain’s glial cells – is the 
most common and deadly malignant primary central nervous system tumor in developed 
countries. Two recently completed clinical trials investigating the use of bevacizumab 
(BEV), a monoclonal antibody, to treat newly diagnosed GBM concomitant with the 
standard-of-care (SOC) showed mixed survival and quality of life outcomes. In this 
study, a cost utility study was conducted to investigate if BEV should be used to treat 
newly diagnosed GBM. A three stage time-dependent Markov model was built using 
survival estimates from the two clinical trials, costs from Ontario residents diagnosed 
with GBM between 2003 and 2011, and literature utility values. The expected 
incremental cost utility ratio for BEV plus the SOC compared to the SOC alone is 
8,393,212 $/quality adjusted life year over a six year period. Therefore, BEV plus the 
SOC is not cost-effective as a first-line therapy. 
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Chapter 1 
1. Introduction 
Glioblastoma Multiforme (GBM), a glioma – cancer of the brain’s glial cells – is the 
most common and deadly malignant primary central nervous system (CNS) tumor in 
developed countries [1]. Approximately three in 100,000 will be diagnosed with GBM 
each year, making it the most common glioma, accounting for approximately 82% of all 
gliomas, and contributing approximately 5% of all adult tumors [2]. There are two 
variants of GBM, giant cell glioblastoma and gliosarcoma (Figure 1). The World Health 
Organization (WHO) uses a four-tier system to classify gliomas. The classification 
increases from one to four based on tumor aggressiveness, anaplasia, and degrees of 
differentiation [1]. The WHO grades GBM as a level 4, the most severe and poorest 
prognostic correlate [3]. The aggressive and incurable nature of GBM has made it a 
burden not only for patients and their families, but for healthcare systems too. As the 
cancer progresses, patients will become dependent on care, increasingly confined to their 
bed, and eventually die from progressive brainstem failure in a comatose state [4, 5].  
Figure 1. Classification flow chart of malignant gliomas 
 
Primary GBM, when the original tumor is GBM, is very difficult to treat and has the 
tendency to progress, transform, or recur; these evolved tumors are termed secondary 
GBMs [3]. Overall, one-year survival probability is 17-30% for newly diagnosed GBM 
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patients with either a primary or secondary subtypes. Two-year survival dramatically 
drops to 3-5% and five-year survival rates remain at a similar 1-3% for patients between 
15 and 45 years of age [6]. Survival, however, drops to 1% for patients aged 75 years and 
above [3].  
 
In contrast, anaplastic astrocytoma, a grade three malignant glioma, has a one-year 
survival probability of 60.1% and a five-year survival of 49.4% [5]. Recurrent GBM, 
when the cancer returns after a period of no tumor detection, has a progression free 
survival (PFS) rate of nine to 10 weeks [7]; one-year survival for recurrent GBM is 20 to 
25% [7, 8]. Response to treatment is seen in fewer than 10% of recurrent GBM patients 
[3]. Additionally, survival does not differ between men and women patients [3]. GBM 
randomized control trials (RCTs) show the best prognosis for patients, with a marked 
increase to 13-26% for overall two-year survival [9]. Early diagnosis has not been seen to 
improve survival outcomes [3].  
 
No molecular factor has been generally acknowledged as a prognostic indicator; 
however, patients with methylation of the promoter O6- methylguanine-DNA 
methyltransferase (MGMT) and IDH1 mutations are associated with longer survival rates 
[10, 11]. Still, age and Karnofsky performance status (KPS) – a performance scale used 
by clinicians to determine a patient’s ability to survive chemotherapy – are the primary 
prognostic factors [12]. Moreover, while not fully meeting the quality of life (QoL) 
definition, the KPS is the earliest measure of QoL in GBM and still is widely used as a 
QoL outcome measure [13].  
 
Primary onset GBM has a relatively older mean age of approximately 62 years, while 
secondary GBM has a younger mean onset age of 45 years [6, 14]. There is a larger 
standard deviation in age for secondary GBM than for primary GBM [6, 15]. Moreover, 
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primary GBM occurs three times more often in males than females while secondary 
GBM occur more often in females than males [6, 15]. 
 
Two clinical trials investigating the use of bevacizumab (BEV), a humanized monoclonal 
antibody targeting vascularization factors, to treat GBM have recently completed and 
showed mixed results in survival and quality of life outcomes [16, 17]. While BEV may 
have a positive clinical effect on treated patients, the cost of treatment is expensive  [18]. 
Therefore, the goal of this thesis is to investigate if the cumulative benefits derived from 
BEV treatment can justify the incurred costs in newly diagnosed GBM. 
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Chapter 2 
2. Literature Review 
2.1. Genetic Pathology 
The GBM tumor usually has a homogenous histology; however, it is genetically 
heterogeneous. Histologically, GBM has significant cellularity, vascularization, mitotic 
activity, and necrosis [7]. Several genetic events can result in GBM proliferation, 
requiring cumulative and subsequent genetic mutations, making it unlikely that one 
mutation can indicate GBM development. Therefore, to increase efficacy and specificity, 
therapies must be tailored to a patient’s specific GBM genotype. 
 
Genetic screens of GBM show scattered mutations throughout the genome, with 
concentrations in the 1p, 6q, 9p, 10p, 10q, 13q, 14q, 15q, 17p, 18q, 19q, 22q and Y-
chromosomes [19-24]. Specifically, the 20q13.33 (RTEL), 7p11.2 (EGFR), 9p21.3 
(CDKN2BAS), 5p15.33 (TERT), 11q23.3 (PHLDB1), and 8q24.21 (CCDC26) genes 
have been weakly associated with the GBM susceptibility. Studies have noted that several 
of these mutations may have been caused by tumorigenesis instead of causing the tumor. 
The most common mutation in GBM, 60-80% of cases, is found on chromosome 10  
[25].  
 
2.2. Molecular Biology 
The phenotypic effects of GBM mediated mutations augment several signaling pathways 
and their normal function. Broadly, the most commonly altered pathways in GBM 
neoplastic cells are repair pathways such as nucleotide excision repair, base excision 
repair, mismatch repair, and direct reversal of lesions in recombination [26, 27]. 
Ultimately, the neoplastic cells have a reduced ability to repair DNA damage and 
mutations. This is why patients with an active O6- methylguanine-DNA 
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methyltransferase (MGMT) expression show better prognosis than those with an inactive 
MGMT [28]. The MGMT promoter is responsible for a tumor suppressor pathway that 
works by protecting against alkylating agents [11]. 
 
Research on GBM altered pathways appears to show that mutation of the epidermal 
growth factor receptor (EGFR) and other tyrosine kinase receptor autocrine signaling 
pathways are often necessary for GBM progression [29]. Tyrosine kinase receptor 
autocrine signaling pathways are responsible for growth, proliferation, migration, and 
tumor vascularization. Mutation of this pathway in GBM results in over expression and 
an amplified effect on neoplastic cells. Moreover, mutation of this pathway results in 
resistance to certain anticancer therapies by limiting the effects of drugs on cell death 
pathways. Tyrosine kinase receptor autocrine signaling amplifications are found more 
often in primary GBM tumors (40-60%) more often than secondary GBM tumors (<10%) 
[30].  
 
Additionally, GBM patients commonly have inactivating mutations in the TP53 and 
retinoblastoma pathways [31, 32]. The TP53 pathway, also known as the guardian of the 
genome, mediates DNA repair by halting the cell cycle in response to radiation or toxin 
exposure and DNA strand breaks [33]. If the damage to the cell is too great, the TP53 
pathway will initiate apoptosis and stop replication. The retinoblastoma pathway interacts 
with the TP53 pathway to pause the cell cycle for maintenance when damage occurs. 
Inactivation mutations in either of these pathways will hinder the cell’s ability to limit 
mutation propagation and undergo apoptosis, ultimately allowing tumorigenesis. 
 
2.3. Etiology and Diagnosis 
The causes of GBM are unknown and the risk factors for tumorigenesis are poorly 
understood. Ionizing radiation exposure is the only environmental factor recognized to 
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cause GBM [34]. However, a study examining children exposed to nuclear bomb 
radiation found no increased risk of GBM [34]. Other exposures like chemical 
carcinogens, vinyl chloride, pesticides, and second-hand smoke have been proposed as a 
cause of GBM; however, etiology has not conclusively been proven [35]. Caucasians are 
at a higher risk of developing GBM when compared to Asians or Africans [14]. 
Interestingly, research has shown that increased socio-economic status can increase the 
risk of GBM development [36]. Additionally, preventative life-style changes are 
ineffectual in deterring GBM. While rare, a familial medical history of GBM has been 
shown to double one’s risk of developing the neoplasm. Ultimately, it is agreed that 
GBM generally spawns from a combination of genetic and environmental factors [15].  
 
Population studies have shown that a few heredity syndromes are correlated with 
increasing GBM risks. These syndromes include Li-Fraumeni neurofibromatosis type 1 
and type 2, Turcot, tuberous sclerosis, Cowden, and familial schwannomatosis [35].  
 
GBM is highly invasive, characteristically spreading through the parenchyma with the 
majority of GBM tumors located in the frontal lobes of the supratentorial compartments. 
GBM can also occur in the brain stem, spinal cord, cerebellum, and cortical areas. In 
most cases, the neoplastic cells are clumped together near the tumor bed or within two 
centimeters of the enhancing boarders. Examiners commonly see vascularization and 
necrosis in GBM, and these characteristics are used to differentiate the tumor from lower-
grade gliomas [37]. Despite GBM’s tendency to metastasize, it does not propagate 
outside the CNS [3]. 
 
2.4. Clinical Presentation and Initial Evaluation 
The most common symptoms of GBM are progressive focal neurologic deficits, seizures, 
and headaches – found in 50% of presenting patients. It is becoming more common to 
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find GBM tumors that are asymptomatic [3]. In patients aged 50 and above, symptoms 
such as new-onset headache, headache localization, and progressive headache severity 
are used to differentiate a typical headache from a possible GBM diagnosis.  
 
Typically, when a patient presents with GBM symptoms, cerebral MRI images are taken 
to examine for neoplasms [3]. Since neoplasms look similar to benign radiation necrosis, 
more complicated techniques such as MR perfusion, F18-fluorodeoxyglucose-position 
emission tomography, and Magnetic Resonance Spectroscopy are sometimes needed for 
diagnosis [38]. Modern imaging techniques have become integral in selecting treatment 
options because they can help identify glioma subgroups [38]. Even though GBM can be 
identified using imaging techniques, a neuropathologist will only make a final diagnosis 
of GBM after confirming a positive brain tumor biopsy [39].  
 
2.5. Disease Management 
Several hundred studies and trials for the clinical treatment of GBM have been published 
since the 1960s [3]. In the late 1960s, whole brain radiation therapy (RT) became the 
standard-of-care (SOC) in GBM management, effectively doubling median survival time 
from four to six month to 10 to 11 months [3]. However, due to certain CNS region’s 
sensitivity to ionizing radiation, RT treatment needed to be limited in intensity and 
duration. Moreover, only patients older than three years old could receive any amount of 
RT treatment due to a newborn’s sensitivity to radiation.  
 
While radiosensitizers and alternative RT strategies have been tried to overcome RT 
limitations, none have shown a clear increase in patient survival [3]. Targeted RT rather 
than whole brain RT is the only change to the treatment showing equal effectiveness at 
destroying GBM tumors with the beneficial side effect of reducing harm to healthy 
peripheral tissue.  
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Prior to 1999, new treatments shifted to the addition of nitrosourea variants, a 
DNA alkylating chemotherapy that can cross the blood-brain-barrier (BBB) forming 
inter-strand crosslinks in DNA, preventing replication [9]. A meta-analysis showed that 
some nitrosoureas (e.g. BCNU) could add up to two months of survival to a patient, and 
therefore a recommendation was made to add BNCU to the SOC regiment [9]. In 2003, 
the use of BNCU has evolved to placing wafers infused with the chemotherapy drug into 
the resection site of the removed tumor [40, 41]. This way, the oncologist can target the 
therapy onto the affected tissue, instead of issuing a systemic treatment affecting non-
neoplastic cells. In the end though, BNCU was not adopted as a GBM management tool 
due to local side effects and costs. 
 
Currently, surgical excision of the tumor has become the first line treatment of GBM. 
Removal of greater than 98% of the tumor has been shown to double survival time up to 
one additional year. However, this amount of excision is difficult as the tumor migrates to 
neighboring parenchymal cells and follows an infiltrative growth pattern rather than an 
expansive one [39, 42, 43]. However, any substantial excision, even less than 98% of the 
tumor mass, reduces intracranial pressure and therefore intracranial related symptoms 
resulting in temporarily improved QoL [44]. While removing less than 98% of the tumor 
reduces immediate mass effect, it does little to improve prognosis [43, 45]. Moreover, the 
residual tumor has shown to behave erratically and aggressively in a malignant fashion 
[43].  
 
2.6. Standard-of-Care 
2.6.1. First Line Treatment  
In 2005, temozolomide (TMZ), another DNA alkylating agent, was added to the SOC for 
newly diagnosed GBM because it had the same benefit as BNCU, as validated by meta-
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analysis, when treated in co-occurrence with RT. TMZ treatment, however, has fewer and 
less intensive severe side effects [46]. Moreover, patient QoL was not negatively 
impacted by adding the TMZ treatment as compared to BNCU [39]. Overall, surgery, 
TMZ, and RT can improve a patient’s overall survival time by up to 14 months [46]. 
TMZ is an imidazotetrazine derivative of dacarbazine and is converted into its active 
form, monomethyl triazone imidazole carboxamide (MTIC), during circulation at 
physiologic pH where it nonspecifically inhibits DNA replication [46]. TMZ, like all 
GBM chemotherapy drugs, has the quality of passing the BBB. 
 
Patients are treated with TMZ in two phases. The first phase, the concurrent phase, starts 
with maximal resection, followed by concurrent RT and oral 75 mg/m
2 
day TMZ, five 
days a week, for a maximum of seven weeks. The second phase, the maintenance phase, 
starts after a four-week break and consists of six cycles. Each cycle is defined as two 
weeks of 150-200 mg/m
2 
TMZ treatments at five days per week, followed by a two-week 
break [16, 17, 47, 48].  
 
2.6.2. Second-Line Treatment 
Virtually all patients will undergo tumor progression during or after first-line treatment 
[49]. A second surgical resection is generally considered to reduce mass effect and update 
tumor molecular and histological characteristics. For a majority of patients through, 
tumor location and physical performance will limit the extent or ability to perform 
surgery [50].  
 
Second-line chemotherapy options include TMZ, BEV, and nitrosoureas. Moreover, 
alternative dosing and scheduling schedules have been explored as options. Nitrosoureas 
such as carmustine and lomustine are usually used to treat recurrent GBM, resulting with 
modest survival effectiveness at best [51]. After TMZ and BEV treatment regimens fail, 
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the patient’s prognosis is extremely poor with a median survival of three to four months 
[50]. 
 
2.7. Cognition and Quality of Life 
As GBM is a cancer of the CNS and occurs in the frontal lobes, cognition – the ability to 
learn, reason, and communicate – can be severely affected during disease progression 
[52]. The effect of cognitive degeneration is difficult to measure because one’s ability to 
learn and reason is tied to their ability to communicate. While a physician is able to 
measure physical performance using a KPS with relative ease, assessing a patient’s 
ability to reason and learn when they have difficulty to communicate is not trivial. It has 
been shown that while cognitive limitations will have a less visible effect on QoL than a 
physical limitation, the impact of cognitive limitations on a patient’s QoL can be as great 
or greater [53]. However, it should be noted that cognition loss is noticed more frequently 
in severe GBM than less progressed GBM [54]. Larger tumor size is correlated to lower 
QoL [55].  
 
In addition to the difficulties in noticing and measuring cognition loss and the resulting 
QoL change, treatment can usher further negative cognitive effect. RT treatment for 
GBM, by its nature, is directed at the brain and has been found to be a cause of cognitive 
decline [56]. Corticosteroid use, necessary to reduce peritumoral edema, has also been 
found to have negative effects such as myopathy and insomnia [57]. As a tumor 
progresses, a high-dose of corticosteroids is required resulting in clinically significant 
negative effects on the patients. While no study to date has evaluated corticosteroid 
impact on QoL, the adverse side effects are widely regarded to result in reduced QoL [52, 
57, 58]. While less studied than corticosteroids, antiepileptic drugs, usually given in 
conjunction with corticosteroids, have been found to impair working memory capacity 
more than RT [56, 59]. Altogether, the tumor, GBM-related epilepsy, RT, chemotherapy, 
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corticosteroids, anti-epileptic drugs, and psychological distress of cancer will contribute 
to cognitive degeneration and loss in QoL.  
 
Early studies used KPS as a proxy for QoL linking physical ability to mental ability [60, 
61]. The studies found that physical performance was maintained after diagnosis for a 
period that is relatively long compared to the survival time a patient has after diagnosis. 
The problem researchers faced was that cognition and psychological condition worsened 
during this period as measured with a patient-oriented questionnaire [62]. Therefore, 
physical performance was not a good measure of cognition and by extension QoL, 
highlighting a need for more accurate, and hopefully patient-oriented, QoL measurement 
strategies [63]. Moreover, as GBM is incurable, the treatment goal is to prolong life and 
increase QoL requiring an accurate measure of both.  
 
Several neurocognitive assessment tools have been developed to meet this need and are 
being used in several clinical trials [44, 64]. The most notable questionnaires are the 
European Organization for Research and Treatment of Cancer Core Quality of Life 
Questionnaire (EORTC QLQ-C30) and the Functional Assessment of Cancer Therapy 
cancer-specific scales (FACT) [65].  
 
2.8. Bevacizumab 
GBM tumors are highly vascularized tumor bodies due their large nutrition requirements. 
Therefore, targeting angiogenic pathways limits vascularization, restricting nutrient 
supply to the growing tumor, and ultimately hindering tumor growth [66]. Current 
strategies to limit vascularization consist of αvβ5 integrins, hepatocyte growth factors, 
and antibodies of vascularization factors like Vascular Endothelial Growth Factor 
(VEGF). The benefit of some of these therapies is that they can target tumor vasculature 
directly [66].  
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BEV is a humanized monoclonal antibody that selectively binds to human VEGF thus 
preventing vascularization. It has shown the most promising clinical results to treat GBM 
to date [67, 68]. Manufactured by Genentech/ Roche, BEV is sold under the trade name 
Avastin and is stored in a 25mg/ml vial [69]. BEV is already approved in the United 
States and Europe as a standard treatment for metastatic colorectal cancer, advanced non-
small cell lung cancer, and metastatic breast cancer [70]. The first studies to evaluate 
BEV in GBM comes from two phase 2 RCTs: the BRAIN and NCI 06-C-0064E studies, 
which spawned two additional large phase 3 RCTs for further clinical study [17, 64, 68]. 
 
The multicenter, non-comparative, phase 2, BRAIN RCT enrolled 82 recurrent GBM 
patients and treated them with BEV with and without irinotecan, a topoisomerase 
inhibitor [71]. For the combination therapy, the investigators found a 38% response rate 
with a six-month progression free survival of 50% and a median overall survival of 8.6 
months [72]. This is a 50% increase in overall survival compared to historical rates [66, 
72, 73]. As a single therapeutic agent, BEV had a 28% response rate with a six months 
progression free survival of 42.6% and median overall survival of 9.2 months [72].  
 
The NCI study enrolled 48 patients with recurrent GBM and treated them with BEV as a 
single therapeutic agent [74]. The study had favorable results: the median progression 
free survival was 16 weeks, 29% six months progression free survival, and median 
overall survival of 31% [74].  
 
Due to these two studies, the FDA accelerated approval of the phase 2 BEV drug to treat 
recurrent GBM following RT and TMZ therapy. However, the EMEA, the European drug 
regulatory agency, did not approve BEV as a treatment for recurrent GBM [75].  
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A meta-analysis of BEV trials found that of a total 621 GBM patients, BEV treatment 
had a median overall survival was 9.3 months (95% CI: 7.9 to 10.6) and SOC had a 
median overall survival of 8.1 months (84, 85). Moreover, six-month progression free 
survival was 45.2% and overall six-month survival was 76.4%  [76]. Altogether, BEV 
has shown promise in treating GBM.  
 
In addition to the potential increase in overall survival and progression free survival, 
BEV has the added benefit in recurrent GBM patients of reducing or eliminating the need 
of corticosteroids [77, 78]. In clinical trials, reduced corticosteroid use resulted in 
increased cognitive function and QoL [71, 78]. Moreover, BEV treated patients 
maintained their KPS levels longer than SOC patients [71].  
 
Most of the side effects of BEV are already known due to its use in other cancer 
therapies, with BEV having the same toxicity in GBM treatment [71, 77]. The most 
common adverse effects of BEV in GBM are low-grade bleeding, hypertension, impaired 
wound healing, and proteinuria. Most of these adverse effects are typical in therapies 
targeting VEGF and are found on-target. Grade two bleeding has been found to occur in 
5.3% of patients, while serious gastrointestinal perforation, reversible posterior 
leukoencephalopathy syndrome, cardiac failure, and wound-healing events occur in fewer 
than 2% of patients [66, 71, 77]. Approximately 3% or fewer of patients will experience 
life-threatening intracranial hemorrhages. BEV trials have found a high risk of 
thromboembolism in patients (1.6% to 12.5%); however, the nature of GBM increases the 
risk of thromboembolism on its own [79]. Overall, BEV has been shown to have 
clinically low risks of life-threatening complications.  
 
As no phase 1 RCT was performed for BEV for newly diagnosed GBM, no BEV SCO 
dose has been established; however, the manufacturing company (Genentech/ Roche) 
recommends 10mg/kg every two weeks for GBM treatment [77]. Two large phase 3 
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RCTs used the recommended BEV dosing during their concurrent treatment phases [17, 
80]. 
 
2.9. Bevacizumab plus SOC for First Line Glioblastoma 
Treatment  
 Reaction to the FDA’s approval of BEV in recurrent GBM was mixed, with many 
healthcare professionals questioning the interpretation of study results [48]. While the 
FDA approved BEV, the EMEA rejected the use of BEV because they questioned the 
accuracy of the CT or MRI scans used to evaluate tumor progression [81]. BEV acts to 
reduce VEGF, and therefore normalize tumor vascularization, which in turn decreases 
cerebral vessel permeability in the scans. This has the effect of reducing contrast-
enhanced components even if the tumor was progressing [82].  
 
Additionally, the FDA evaluated the uncontrolled BEV clinical trial data against 
historical controls. Effectively, BEV was compared against a control group that may have 
experienced different environmental exposures and treatment [83].  
 
Two phase 3, double-blinded, randomized control clinical trials were completed to 
evaluate BEV for first line GBM. The Avastin in Glioblastoma (AVAglio) trial was 
industry sponsored [16], while the Radiation Therapy Oncology Group (RTOG) 0825 
clinical trial was publicly sponsored [17]. The results from both trials were presented at 
the 2013 American Society of Clinical Oncology (ASCO) meeting [48]. Currently, BEV 
has not been added to the SOC [48].  
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2.9.1. AVAglio Clinical Trial 
The F. Hoffmann-La Roche sponsored AVAglio trial enrolled 921 patients from 120 sites 
in 23 countries to evaluate concomitant BEV plus the SOC to treat newly diagnosed 
GBM patients [16, 64]. The trial had two co-primary endpoints: progression free survival 
and overall survival. The first co-primary endpoint, progression free survival, was 80% 
powered to detect a 0.77 (two sided alpha of 1%) hazard ratio, with the second co-
primary endpoint, overall survival, 80% powered to detect a 0.80 (two sided alpha of 4%) 
hazard ratio [64]. The overall significance divide was weighted towards overall survival, 
as it is a typical endpoint in phase 3 clinical trials. QoL measurements were defined as a 
secondary endpoint and therefore mandatory for all patients. Exploratory analysis was 
performed to investigate predictive biomarkers intended to aid clinicians in identifying 
future candidates receptive to BEV for first line treatment [64]. 
 
The patient population was defined as those greater or equal to 18 years of age, with 
newly diagnosed, histologically confirmed, supratentorial GBM [64]. The main exclusion 
criteria include prior chemotherapy or immunotherapy for GBM or low-grade 
astrocytoma, prior radiation therapy to the brain, recent intracranial hemorrhage, history 
of intracranial abscess, non-healing wound, active ulcer, and untreated bone fracture [64]. 
 
Eligible patients received tumor excision or biopsy and were randomized to a treatment 
arm between 28 and 49 days post-surgery. All patients received 2Gy of local irradiation, 
five days per week, for six weeks concomitant with 75mg/m
2
 oral TMZ every day, for a 
maximum of 49 days during the concomitant phase. The maintenance phase commenced 
after a four-week break where patients were given 150-200 mg/m
2 
of oral TMZ daily on 
days one to 5, each week, for four weeks. The maintenance phase cycle was repeated six 
times for a maximum total of 24 weeks. BEV plus the SOC patients received 10 mg/kg 
intravenous every two weeks during the concomitant phase and maintenance phase, and 
15 mg/kg every three weeks during the monotherapy phase, post maintenance phase, until 
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disease progression. SOC patients were given placebo instead of BEV [64]. Imaging used 
to evaluate tumor progression was evaluated by central review [64]. 
 
Once the patient experienced tumor progression, the study protocol allowed patient arm 
crossover for progression treatment at the discretion of the treating physician. 31% of the 
overall study patient population received further BEV treatment and 35.6% were treated 
with TMZ [84]. Moreover, up to 30% of control patients are estimated to have received 
BEV during tumor progression [85]. 
 
The AVAglio trial showed a significant improvement in progression free survival, but 
failed in overall survival. The median BEV plus the SOC arm progression free survival 
was 10.6 month compared to the control’s 6.2 months (p<0.0001; hazard ratio=0.64); 
median overall survival was similar, albeit slightly longer, between the BEV plus the 
SOC and SOC arm (16.8 months vs. 16.7 months; p=0.10; hazard ratio=0.88). No new 
toxicities were seen in the BEV plus the SOC treated population; however, serious 
adverse events were more common in the experimental arm compared to the SOC arm 
[16]. 
 
The AVAglio trial investigated QoL measures using a pre-specified five dimensions from 
the EORTC QLQ-C30 survey with brain module (global health status, communication 
deficits, physical function, social function, motor dysfunction). The trial found a 
significantly longer period of deterioration free survival in the BEV plus the SOC arm 
compared to SOC. Moreover, BEV patients had a statistically longer period without 
corticosteroids and a Karnofsky performance score above 70 [16]. 
 
No biomarker evaluated in the exploratory analysis was determined to be a good 
predictor of BEV response [16]. 
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2.9.2. RTOG 0825 Clinical Trial 
The Radiation Therapy Oncology Group (RTOG) who collaborated with the North 
Central Cancer Therapy Group (NCCTG), and Eastern Co-operative Oncology Group 
(ECOG) sponsored the RTOG 0825 trial. 637 patients from were included in the study 
[17]. Similar to the AVAglio study, the RTOG 0825 trial had two co-primary endpoints: 
progression free survival and overall survival. The co-primary endpoints were jointly 
80% powered to detect a 30% reduction (two sided alpha of 0.4%) in progression free 
survival hazard and 25% reduction (two sided alpha of 4.6%) in overall survival hazard. 
QoL measures were classified as a tertiary endpoint, and therefore not mandatory for 
patients to complete. Similarly to the AVAglio trial, exploratory analysis was conducted 
to identify bevacizumab efficacy biomarkers [17].  
 
The study population was similar to the AVAglio trial, with patients only receiving tumor 
biopsy excluded. All RTOG 0825 patients were randomized to a trial arm within three to 
five weeks post-surgery, and received a similar treatment regimen to patients in the 
AVAglio trial. Main differences in treatment were that BEV plus the SOC arm patients 
received three weeks of BEV during the concomitant phase, rather than six weeks in the 
AVAglio trial, and 12 weeks of TMZ and BEV during the maintenance phase, rather than 
a maximum of 24 weeks in the AVAglio trial. Imaging used to evaluate tumor 
progression was evaluated to clinical investigators.  
 
Similar to the AVAglio trial, once tumor progression occurred, the protocol allowed for 
patient arm crossover. Crossover was pre-specified to either BEV, concomitant BEV plus 
TMZ, or concomitant BEV and irinotecan therapies. 20.9% of patients in the BEV arm 
received a BEV regimen, while 40.9% or patients in the SOC arm received a BEV 
regimen during progression treatment.  
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Neither of the RTOG 0825’s primary endpoints, progression free survival or nor overall 
survival, reached significance. BEV was associated with a longer median progression free 
survival (10.3 vs. 7.3 months; p=0.007; hazard ratio=0.79) compared to the SOC arm. 
Median overall survival, however, was slightly shorter in the BEV arm compared to 
placebo (15.7 vs. 16.1 months; p=0.021; hazard ratio=1.13) [17]. 
 
The RTOG 0825 trial evaluated QoL by longitudinal analysis of two QoL surveys (MD 
Anderson Symptom Inventory Brain Tumor survey and EORTC QLQ-C30 with brain 
module). The trial reported that BEV patients experienced a significant worsening of QoL 
as compared to control patients [17].  
 
The RTOG 0825 trial did find a molecular signature showing a relationship of increased 
overall survival in BEV patients [17]; however, the observation requires prospective 
validation [84].  
 
2.9.3. Controversy Between AVAglio and RTOG 0825 
Both the AVAglio and RTOG 0825 trials employed similar study designs and reported 
similar trends in survival outcomes (Table 1). However, contradictory progression free 
survival and QoL results were reported, in addition to a puzzling overall survival 
outcome. These differences are described in more detail below. 
 
2.9.3.1. Differences – Progression Free Survival Outcomes 
The AVAglio and RTOG 0825 trials reported an increased progression free survival in 
the BEV plus the SOC arm in comparison to the SOC arm (10.6 and 10.3 in the BEV plus 
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the SOC arm compared to 6.2 and 7.3 months in the SOC arm respectfully). However, the 
difference was reported as significant in the AVAglio trial and non-significant in the 
RTOG 0825 trial. The difference in significance result is due to a larger alpha value 
attributed to progression free survival in the AVAglio trial as compared to the RTOG 
0825 trial (1% and 0.4% respectively). Therefore, the AVAglio trial reached its 
significance level while to RTOG 0825 trial did not.  
 
2.9.3.2. Differences – Quality of Life Measures  
QoL measures reported between the two trials were also contradictory. The AVAglio trial 
reported that QoL of patients receiving BEV was maintained for a three to four month 
longer period of time as compared to control patients. The RTOG 0825 trial, however, 
reported that BEV patients experienced a decrease in QoL as compared to control 
patients. This contrast in study results is likely multifactorial, and may be associated to 
study design differences specified in each trial. The AVAglio trial had looser eligibility 
criteria as compared to the RTOG 0825 in that AVAglio accepted patients whom only 
received biopsy while the RTOG 0825 did not. Therefore, the AVAglio trial would allow 
patients with a larger tumor burden into the study [86]. Moreover, the AVAglio trial 
specified QoL measures as a secondary outcome requiring all patients to complete the 
surveys, while the RTOG 0825 specified QoL as a tertiary outcome. As seen in reported 
outcomes, the RTOG 0825 QoL assessment saw significant patient attrition over the trial 
period [17].  
 
Additionally, the AVAglio trial measured QoL as the median time to a ≥10 point QoL 
survey deterioration from baseline with no improvement, disease progression or death 
whereas the RTOG 0825 trial also looked at progression free patients but measured QoL 
using discrete time point analysis and longitudinal general linear modeling. The two 
methods analyzing QoL outcomes are very different and make a direct comparison 
difficult.  
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Finally, the RTOG 0825 measured radiological response using the traditional Macdonald 
criteria which does not account for non-enhanced tumor progression, while the AVAglio 
study used similar response criteria as defined the by the Response Assessment in Neuro-
Oncology Working Group which does account for non-enhanced disease progression 
[87]. The consequence of the study design difference could be that the RTOG 0825 trial 
would disproportionally and incorrectly classify early progression BEV patients as 
progression free, compared to control patients, and include them in the progression free 
QoL analyses [85].  
 
Numerically, the RTOG 0825 saw 79.4% of its population complete a baseline QoL 
questionnaire, while the AVAglio study had all patients complete a baseline 
questionnaire. No statistical differences, using a 5% alpha, were found between the 
baseline characteristics of patient who completed the baseline questionnaire versus those 
who did not in the RTOG 0825 RCT. 
Table 1. Summary of the AVAglio and RTOG 0825 clinical trials 
Point of Comparison AVAglio RTOG 0825 
Study Design Double blind placebo-
controlled 
Double blind placebo-
controlled 
Primary Endpoint PFS and OS co-primary PFS and OS co-primary 
Secondary Endpoint QoL - 
Tertiary Endpoint - QoL and neurocognitive 
function 
Eligibility Biopsy only patients 
allowed; multifocal tumors 
allowed 
Biopsy only patients 
excluded; multifocal tumors 
excluded 
Statistical Significance Overall α=0.05, PFS α=0.01; 
OS α=0.04 
Overall α=0.05, PFS 
α=0.004; OS α=0.046 
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Table 2 Continued. Summary of the AVAglio and RTOG 0825 clinical trials 
Point of Comparison AVAglio RTOG 0825 
Start of Chemotherapy >28 and ≤ 49 days after 
surgery 
>21 and ≤ 35 days after 
surgery 
Number of TMZ Cycles 6 12 
Start of BEV Day 1 Day 28 
Continuation of BEV Until progression Until progression 
Assessment of Progression Enhanced and non-enhanced 
imaging; clinical assessment 
Enhanced imaging; clinical 
assessment 
Unbinding and Arm 
Crossover at Progression 
Not planned, but anticipated Planned 
   
Number of Patients 921 637 
Percentage of Patients 
with Total Tumor 
Resection 
41% Bev, 42.3% TMZ 63% Bev, 59% TMZ 
PFS Months (Median) Bev – 10.6 
TMZ – 6.2 
Bev – 10.7 
TMZ – 7.3 
PFS Hazard Ratio 0.64 (95% CI 0.55-0.74) 0.79 (95% CI 0.66-0.94) 
OS Months (Median) Bev – 16.8 
TMZ – 16.7 
Bev – 15.7 
TMZ – 16.1 
OS Hazard Ratio 0.88 (95% CI 0.76-1.02) 1.13 (95% CI 0.93-1.37) 
QoL Longer time to definitive 
deterioration with BEV 
Worsening with BEV for 
some QoL components 
 
2.9.3.3. Overall Survival Outcomes 
It is interesting that both trials showed a marked increase in progression free survival, 
while no increase in overall survival. Several theories as to why this result was reported 
have been published without any conclusive response.  
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The first theory focuses on the study arm crossover design used in both trials, which 
allowed patients in both arms to receive BEV during tumor progression. Therefore, it is 
possible that BEV slows tumor development, an effect nulled by patients in the SOC arm 
receiving BEV [48]. The second theory explores tumor resistance to BEV therapy by 
upregulating pro-angiogenic signaling pathways already upregulated by BEV treatment. 
Therefore, new blood vessels develop from pre-existing vessels through angiogenesis, 
rather than de novo formation of endothelial cells via vasculogenesis [88, 89]. The third 
theory is based on increased tumor aggressiveness post BEV treatment. Moreover, the 
BEV experienced tumors did not seem to respond to additional or subsequent BEV 
treatments [90, 91]. As study arm crossover at tumor progression was allowed in both the 
AVAglio and RTOG 0825 trials, and no SOC arm was designed in the BRAIN study, it is 
currently unclear whether BEV can extend overall survival.  
 
Overall, the current BEV studies did not find a significant increase in overall survival for 
newly diagnosed GBM. It does, however, show that progression free survival is 
increased, a state that is considered to have higher QoL compared to progression, at the 
expense of increased toxicity [44]. The current lineup of therapies for newly diagnosed 
GBM is limited and similarly does not provide solutions to increased overall survival. 
Clinicians are starting to question, in the interim of finding a solution for overall survival, 
whether attention should be focused on progression free survival and QoL [48, 84, 85, 92, 
93].  
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Chapter 3 
3. Chapter: Research Question 
The purpose of this study is to conduct a cost-utility assessment of BEV treatment for 
newly diagnosed GBM concomitant with TMZ, the SOC, compared to the SOC alone 
across all health states. It evaluates the incremental cost utility ratio of BEV plus the SOC 
compared to the SOC using real-world costs and event rates to understand if the new 
BEV plus the SOC is cost-effective, and therefore a candidate, to treat GBM as a first-
line therapy.  
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Chapter 4 
4. Materials and Methods 
An economic model was constructed to compare the cost utility of BEV plus the SOC 
compared to the SOC. A microsimulation model was used to calculate an incremental 
cost utility ratio (ICUR) to allow to for time dependent transition probabilities, time 
dependent event and costs, and time dependent quality of life measures. Survival data 
from the AVAglio and RTOG 0825 trials was used to calculate transition probabilities. 
Health records from Ontario patients were used to calculate costs and event distributions 
for the SOC arm. Relative risks from the AVAglio and RTOG 0825 applied to the SOC 
arm was used to calculate cost and event distributions for the BEV plus SOC arm. 
Published utility measures were used for both arms.  
 
4.1. Cost Effectiveness Model 
4.1.1. Model Structure 
GBM patient health states segment into three categories: progression free tumor, tumor 
progression, and death (Figure 2) [94-96].  
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Figure 2. Progression states and transition directions in Markov model of GBM treatment 
during each one-month cycle 
 
The progression free tumor state is where a patient is diagnosed and treated for GBM, but 
the disease does not progress in severity or size. The patient can remain in this state as 
long as treatment remains effective. If however, the GBM tumor stops responding to 
treatment and starts to progress, the patient transitions from the progression free state to 
the tumor progression state. Once in the progression state, the patient cannot return to the 
progression free state, but remains in the progression state until they transition into the 
death state. Additionally, due to background death rates, a patient in the progression free 
state can enter the death state. 
 
Pooled AVAglio and RTOG 0825 survival data was used to calculate and populate the 
transition probabilities from progression free to progression states, called progression free 
survival, and the transition probabilities from progression to death for both the TMZ and 
Tumor 
Progression 
Progression 
Free Tumor 
Death 
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BEV. The existing RCTs do not directly evaluate the transition probabilities from 
progression to death; they instead calculate the probability of transferring through the 
entire model, from progression free to death termed overall survival. Therefore, both the 
model’s progression free survival and overall survival matched progression free survival 
and overall survival seen in the literature.  
 
A Markov model was built in TreeAge to analyze the cost-effectiveness of BEV 
concomitant with the SOC compared to the SOC along in newly diagnosed GBM [97]. 
As represented in Figure 2’s model structure, the TreeAge Markov model had three states 
(Figure 3): progression free, progression, and death. 
 
 
Figure 3. A TreeAge diagram of a Markov model used to calculate the cost-effectiveness 
of BEV added to the standard of care compared to the SOC for newly diagnosed GBM 
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This cost-effectiveness study is conducted from the public payer’s perspective. This study 
will use a WTP threshold of three times the 2014 GDPC as reported by the World Bank: 
$132,264  [98].  
 
4.2. Data Sources 
4.2.1. Survival Probabilities 
The model’s survival probabilities were collected from the AVAglio and RTOG 0825 
published progression free survival and overall survival Kaplan-Meier curves [16, 17]. 
These phase 3 double blind randomized controlled trials directly compared the two 
interventions examined in this cost-effectiveness study.  
 
4.2.2. Costs 
Costs parameters for this study were collected from patient-level Ontario administrative 
health records through the CD-Link program (Table 3). The CD-Link program access the 
primary, secondary, tertiary, and drug claim costs when submitted to the Ontario Ministry 
of Health and Long-Term Care for reimbursement. Patient level records are linked using 
each Ontario resident’s Ontario Health Insurance Plan (OHIP) number and tracked 
longitudinally. Patients were identified as diagnosed with GBM using the Ontario Cancer 
Registry (OCR) and tracked using several databases: OHIP, Discharge Abstract Database 
(DAD), National Ambulatory Care Reporting System (NACRS), New Drug Funding 
Program (NDFP),and Ontario Drug Benefit (ODB). The OHIP database captures primary 
and secondary care, the DAD captures inpatient hospitalizations and same-day-surgeries, 
while the NACRS captures emergency department visits. The ODB database captures 
listed out of hospital pharmacy claims while the NDFP was used to capture in hospital 
chemotherapy administration.  
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Table 3. List and description of healthcare databases acceded under the CD-Link program 
to evaluate the costs incurred by glioblastoma patients in Ontario 
Database Name Database Description 
Ontario Cancer Registry (OCR) Contains the diagnostic test results, diagnosis, 
treatment information of cancer patients in 
Ontario  
Ontario Health Insurance Plan (OHIP) Contains the billing claims of ~94% of Ontario 
physicians with a fee-for-service practice 
Discharge Abstract Database (DAD) Contains administrative, clinical, and 
demographic discharge notes from acute care 
and same-day surgery hospitalizations 
National Ambulatory Care Reporting 
System (NACRS) 
Contains administrative, clinical, and 
demographic discharge notes from emergency 
department visits 
New Drug Funding program (NDFP) Contains financially covered intravenous cancer 
drugs approved for treatment in Ontario 
hospitals 
Ontario Drug Benefit (ODB) Contains the prescriptions billing claims made to 
the Ontario Ministry of Health and Long-Term 
Care  
 
As no patients in Ontario received BEV, the NDFP was used to identify patient height, 
weight, progression state costs, and BEV cost per kg in non-GBM cases. 
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Prior studies have shown the OHIP, DAD, and OCR databases to accurately represent the 
Ontario general population with excellent coverage [99-101].  
 
4.2.3. Utilities 
Health utility values were gathered from a study by Garside et al.  [44], which evaluated 
the cost-effectiveness of carmustine implants, and TMZ in newly diagnosed GBM. The 
Garside et al. study used the standard gamble method to calculate the utility of a GBM 
patient receiving the SOC during the concomitant and maintenance phase of their 
treatment. Therefore, the relationship between the health state and the QoL was 
determined by actual GBM patients within a health state describing their QoL. As was 
stated in the Garside et al. study, health utility values in the progression free state were 
assumed to remain constant at the progression free value. Once a patient progresses into 
the progression state, the utility value would decrease by 0.02 quality adjusted life years 
(QALY) for each incremental month until the patient entered the death state. [44]. Health 
utility values for patient in the progression state were restricted to a minimum of 0 
QALY.  
 
4.3.  Survival Analysis 
4.3.1. Reconstructing Individual Patient Values  
Results from both the AVAglio and RTOG 0825 clinical trials were included in this 
study; however, individual patient data was not published for either study. For a cost 
utility analysis, a placebo or base case arm and treatment effect is required for transition 
probabilities into various health states. The placebo arm can be estimated using least 
squares or graphical methods from the published graphs while treatment effect is 
typically reported as a hazard ratio [102-104].  
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The drawbacks of least square or graphical methods include accuracy of the digitizing 
software, the applicability of the parametric model used to recreate the survival curve, 
and the assumptions required to extrapolate treatment horizons. Additionally, the use of a 
hazard ratio to estimate the treatment arm implies the proportional hazard’s assumption – 
an assumption that is rarely tested [104]. Moreover, this study requires evidence synthesis 
of the two trials. Therefore, an algorithm developed by Guyot et al. was used to estimate 
individual patient data using digitized Kaplan-Meier curves and pooled together to 
generate transition probabilities [105].  
 
Published in 2012, the Guyot et al. method uses an iterative algorithm that first estimates 
the number of censored cases within an interval. Using this initial estimate, the number of 
censored cases between Kaplan-Meier coordinates is calculated. The algorithm then 
calculates the number of events within the interval and number at risk at the start of the 
next interval. If the number reported at risk and the number estimated at risk do not equal, 
the process is repeated until the two numbers are aligned [102, 105].  
 
Wan et al. used Monte Carlo simulations to test the Guyot et al. algorithm and estimate 
its accuracy. They found that the method’s estimates were better than least squared and 
graphical methods when tested on Weibull distributed survival outcomes. Moreover, the 
Guyot et al. method performed better than an alternative method developed by Hoyle and 
Henley when tested on lognormal distributed survival outcomes [102].  
 
4.3.2. AVAglio Survival Analysis  
Published progression free and overall survival Kaplan-Meier curves from the AVAglio 
study were digitized, converted into individual patient data using the Guyot et al. method, 
and recreated for validation. The AVAglio trial reported a progression free survival 
hazard ratio of 0.64 (95% CI, 0.55-0.74) and a statistically significant difference in 
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survival distributions using a log-rank test (p<0.001) (Figure 4). The recreated 
progression free survival Kaplan-Meier curves reported a hazard ratio of 0.65 (95% CI, 
0.56-0.75) with a significant log-rank test (p<0.001) closely approximating the original 
curve (Figure 4). 
 
Figure 4. Published and recreated AVAglio clinical trial progression free survival 
Kaplan-Meier curves of the two treatment arms 
 
The AVAglio trial reported an overall survival hazard ratio of 0.88 (95% CI, 0.79-1.02) 
with no statistical difference in survival distribution (p=0.10) (Figure 5). The recreated 
AVAglio overall survival reported a hazard ratio of 0.90 (95% CI, 0.78-1.05) with no 
statistical difference in survival distribution (p=0.194). Similar to the recreated 
progression free survival Kaplan-Meier curves, the overall survival recreated Kaplan-
Meier curves closely approximate the published AVAglio overall survival Kaplan-Meier 
curves (Figure 5).  
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Figure 5. Published and recreated AVAglio clinical trial overall survival Kaplan-Meier 
curves of the two treatment arms  
 
4.3.3. RTOG 0825 Survival Analysis  
Similar to the AVAglio trial, the RTOG 0825 clinical trial published progression free 
survival and overall survival Kaplan-Meier curves. Both the published charts were 
digitized, converted into individual patient data using the Guyot et al. method and 
recreated for validation [105]. The RTOG 0825 reported a progression free survival 
hazard ratio of 0.79 (95% CI, 0.66-0.94) with a statistical difference in survival 
distributions as per a log-rank test (p=0.007) (Figure 6). The recreated progression free 
survival outcomes had a 0.78 hazard ratio (95% CI, 0.65-0.92) with a statistical 
difference in survival distribution (p=0.004). The recreated Kaplan-Meier curves closely 
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approximate the published RTOG 0825 progression free survival Kaplan-Meier curves 
(Figure 6). 
 
Figure 6. Published and recreated RTOG0825 clinical trial progression free survival 
Kaplan-Meier curves of the two treatment arms 
 
The RTOG 0825 trial reported an overall survival hazard ratio of 1.13 (95% CI, 0.93-
1.37) with no statistical difference in survival distribution (p=0.21) (Figure 7). The 
recreated individual patient data reported an overall survival hazard ratio of 1.11 (95% 
CI, 0.92-1.35) with no statistical difference in survival distributions (p=0.29). The 
recreated Kaplan-Meier curves closely approximate the published RTOG 0825 overall 
survival Kaplan-Meier curves (Figure 7). 
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Figure 7. Published and recreated RTOG 0825 clinical trial overall survival Kaplan-
Meier curves of the two treatment arms  
 
4.3.4. Pooled Survival Analysis 
To incorporate both clinical trials into the cost-effectiveness analysis, each respective 
trials’ progression free survival and overall survival outcomes needed to be synthesized 
into a single progression free and overall survival metric. A meta-analysis of the hazard 
ratios could be used, however, the proportional hazard’s assumption needs to hold true 
for an accurate pooled metric [104, 105]. To test the proportional hazard assumption two 
methods were used: graphical evaluation of the estimated log transformed survival curves 
(e.g. ln(-ln(survival probability))), and goodness-of-fit test [106].  
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The graphical estimated log transformed survival curves transform the estimated survival 
curves for each outcome by calculating the negative natural log of each curve twice. 
Therefore, if the proportional hazards assumption holds, the transformed survival curves 
should be approximately parallel [106].  
 
The goodness-of-fit test is appealing to researchers because it requires less discretion on 
whether the transformed survival curves are parallel. To test the proportional hazards 
assumption using a goodness-of-fit test, the Schoenfeld residuals were evaluated on 
functions of time. For the proportional hazard’s assumption to hold, the Schoenfeld 
residuals over time should have a non-significant zero slope. If the slope p-value is less 
than 0.05, we can determine that the proportional hazards assumption does not hold 
[106]. 
 
Using the graphical test evaluating the proportional hazards assumption, we can see that 
the progression free survival curves for both the AVAglio (Figure 8) and RTOG 0825 
(Figure 9) clinical trials are not parallel. Moreover, the Schoenfeld residuals slope has a 
statistically significant slope (AVAglio p-value <0.0001, ROTG 0825 p-value<0.0001). 
The transformed overall survival curves, however, are parallel for both the AVAglio 
(Figure 10) and RTOG 0825 trials (Figure 11), with the Schoenfeld residuals slope not 
having a statistically significant slope (AVAglio p-value =0.387, ROTG 0825 p-
value=0.0642). 
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Figure 8. Transformed published AVAglio progression free survival curves of the two 
treatment arms 
 
Figure 9. Transformed published RTOG 0825 progression free survival curves of the two 
treatment arms 
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Figure 10. Transformed published AVAglio overall survival curves of the two treatment 
arms 
 
Figure 11. Transformed published RTOG 0825 overall survival curves of the two 
treatment arms 
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As the proportional hazards assumption does not hold for the progression free survival 
outcomes for both the AVAglio and RTOG 0825 clinical trials, a meta-analysis of the 
hazard ratios is not appropriate. Therefore, both trials’ progression free survival and 
overall survival individual patient data is aggregated respectively to estimate the pooled 
progression free survival curve (Figure 12) and overall survival curve (Figure 13). As the 
proportional hazards assumption does not hold for the progression free survival curves, a 
hazard ratio is not appropriate. However, a log-rank test shows that the survival 
distributions of the two curves are statistically different (p-value < 0.001). Contrastingly, 
the proportional hazards assumption does hold for the overall survival curves, and 
therefore a hazard ratio can be reported. The overall survival hazard ratio is 0.98 (95% 
CI, 0.87-1.10) indicating a non-significant benefit to using BEV plus SOC compared to 
SOC alone for first-line GBM. Similarly, a log-rank test shows no statistical difference in 
overall survival distributions (p-value = 0.709). 
 
 
Figure 12. Pooled recreated progression free survival curves from the AVAglio and 
RTOG 0825 clinical trials of the two treatment arms  
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Figure 13. Pooled recreated overall survival curves from the AVAglio and RTOG 0825 
clinical trials of the two treatment arms  
 
4.3.5. Survival Analysis Time Horizon  
Given the pooled survival outcomes, the maximum time horizon that can be modeled is 
30 months. However, five-year overall survival outcomes are published and are valid 
time horizons for GBM [5]. Therefore, the pooled progression free survival and overall 
survival curves should be projected forward to estimate survival percentages up to five 
years.  
 
To project the pooled progression free and overall survival curves forward to a five year 
(60 months) time horizon, a parametric model was fitted to the existing curves and 
estimated forward. The following distributions were tested for fit: Generalized gamma, 
Generalized F, Log-normal, Gamma, Weibull, Exponential, and Gompertz. 
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For each of the fitted models, the Akaike Information Criterion (AIC) value was 
calculated. The model with the smallest AIC was chosen as the model with the best fit 
[107]. Afterwards, a graphical validation of fit was performed between the pooled 
survival curve and the parametric curve. The final five-year survival curve used pooled 
survival estimates where possible, after which the best-fit parametric function was used. 
 
The pooled progression free survival SOC arm was best fit by a generalized gamma 
distribution (Table 4), while the BEV plus SOC arm was best fit by a Generalized F 
distribution (Table 5). Verifying fit using a graphical method, the two parametric models 
align well with the pooled progression free survival arms (Figure 13). 
 
Table 4. Calculated AIC of fitted parametric models to pooled progression free survival 
SOC arm 
Distribution AIC 
Gompertz 4337.317 
Exponential 4335.481 
Weibull 4321.851 
Gamma 4306.599 
Log-normal 4231.256 
Generalized F 4229.912 
Generalized gamma 4227.909 
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Table 5. Calculated AIC of fitted parametric models to pooled progression free survival 
BEV plus SOC arm 
Distribution AIC 
Exponential 4465.777 
Gompertz 4363.153 
Weibull 4282.523 
Log-normal 4276.911 
Gamma 4264.200 
Generalized gamma 4262.964 
Generalized F 4260.803 
 
 
Figure 14. Best fit parametric models overlaid on pooled progression free survival curves 
 
Using the same approach, all parametric models were fitted to the pooled overall survival 
curve and the AIC was calculated. The SOC (Table 6) and BEV plus SOC (Table 7) 
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survival curves were better fit by a Generalized F model. When we graphically check the 
fit of the parametric models, we can see an overall alignment (Figure 15).  
 
Table 6. Calculated AIC of fitted parametric models to pooled overall survival SOC arm 
Distribution AIC 
Exponential 4464.264 
Gompertz 4396.818 
Log-normal 4390.113 
Weibull 4353.332 
Generalized gamma 4351.129 
Gamma 4349.144 
Generalized F 4344.056 
 
Table 7. Calculated AIC of fitted parametric models to pooled overall survival BEV plus 
SOC arm 
Distribution AIC 
Exponential 4542.277 
Gompertz 4451.422 
Log-normal 4409.961 
Weibull 4390.536 
Generalized gamma 4383.37 
Gamma 4381.543 
Generalized F 4353.962 
 
43 
 
 
Figure 15. Best fit parametric models overlaid on pooled overall survival curves 
 
4.3.6. Markov Model Transition Probabilities 
The transition probabilities guiding the chances of changing health states were derived 
using the pooled progression free and overall survival curves. Strictly, a Markov model is 
governed by the Markov property – the memoryless property of a stochastic process 
[108]. That is to say, the probability of changing health states is dependent only on the 
current health state, and therefore requires no memory of the time spent in that health 
state or any state prior. This would imply that the chances of tumor progression would 
not change if someone were in the progression free state for a short period or a long 
period. In order to accommodate time dependent transition probabilities, an adapted 
Markov process – time-varying transition probability Markov model – was used in this 
study’s model. Therefore, the time spent within a health state can impact the chance of 
changing health states.  
 
The progression free survival to progression health state transition probabilities were 
calculated using Equation 2  [108]. The probability of transitioning from a progression to 
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death health state was solved using a trial and error method until the modeled and true 
overall survival curves aligned. 
 
Equation 1. Formula used to calculate the survival estimates for the progression free 
survival arms 
?̂?(𝑡) =  ∏
𝑛𝑖−𝑑𝑖
𝑛𝑖
= ∏ 𝑃𝑟(𝑃𝐹𝑆 𝑠𝑢𝑟𝑣𝑖𝑣𝑎𝑙)𝑖𝑡𝑖<𝑡𝑡𝑖<𝑡        (1) 
 
Equation 2. Formula used to calculate the transition probabilities for progression free 
survival arms 
Pr (𝑃𝐹𝑆 𝑆𝑢𝑟𝑣𝑖𝑣𝑎𝑙)𝑖 =
?̂?(𝑡+1)
?̂?(𝑡)
          (2) 
 
4.3.7. Validation of Markov Model 
The true progression free and overall survival SOC and SOC and BEV survival arms 
were compared to the modeled progression free and overall survival SOC and SOC and 
BEV survival arms to ensure similarity. Using the graphical method, we can see that the 
modeled arms closely align with the true survival arm for all four survival curves – SOC 
progression free survival (Figure 16), SOC overall survival (Figure 17), SOC and BEV 
progression free survival (Figure 18) and SOC and BEV overall survival (Figure 19). 
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Figure 16. Modeled and true SOC progression free survival curves  
 
 
Figure 17. Modeled and true SOC overall survival curves 
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Figure 18. Modeled and true SOC and BEV progression free survival curves 
 
 
Figure 19. Modeled and true SOC and BEV overall survival curves 
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4.4. Costs and Event Distributions 
In this study, costs were estimated in $CAD (2011) per unit of resource consumed. Total 
costs are composed of two components: the dollar per procedure/diagnosis, and the 
number of procedures/diagnosis. Therefore, we can evaluate the total costs as the product 
of dollar per unit and the number of units. As this study evaluated the SOC and SOC and 
BEV option over the course of time, the distribution of events is of importance.  
 
In Ontario, which is the source of the cost and event distribution data for this study, SOC 
and BEV are not approved as a first-line therapy for GBM. Therefore, the costs and event 
distributions for the SOC and BEV plus the SOC arm are estimated using a combination 
of adverse events (AE) reported in the AVAglio and RTOG 0825 clinical trials, and the 
SOC AE event and costs in the Ontario health record data.  
 
4.4.1. Patient Selection 
In order to align the population in the AVAglio and RTOG 0825 clinical trials, and the 
population contributing event distribution and costs, the same inclusion exclusion criteria 
were used [17, 64]. To be selected for the cost component for the study, a patient must 
have: 
1. Newly diagnosed with histologically confirmed supratentorial GBM between 
2003- 2012, 
2. Received TMZ therapy,  
3. Aged 18 or older,  
4. Not have had a prior malignancy, except for non-melanotomatous skin cancer 
within the three years prior to index,  
5. Not have metastasis below the tentorium, 
6. Not have prior head or neck radiosensitizers, 
7. Not have other co-morbidities or complications within various pre-index periods – 
Appendix 
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A full list of exclusion criteria with diagnosis codes can be found in the appendix 
(Appendix). Overall, costs were extracted from 967 Ontario patients (Table 8). 
Table 8. Cohort patient characteristics N= 967 
Index Year Distribution 
2003 7.65% 
2004 9.93% 
2005 9.82% 
2006 10.55% 
2007 12.10% 
2008 11.17% 
2009 13.24% 
2010 14.27% 
2011 11.27% 
Cause of Death 
GBM 48.60% 
Other 4.24% 
Unknown 47.16% 
Age Category 
18-29 2.38% 
30-34 1.96% 
35-39 2.28% 
40-44 4.24% 
45-49 7.86% 
50-54 12.10% 
55-59 12.72% 
60-64 15.93% 
65-69 19.03% 
70-74 12.62% 
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Table 9 Continued. Cohort patient characteristics N= 967 
Age Category Continued Distribution 
75-79 6.93% 
80-84 1.55% 
85-high 0.41% 
Number of Primary Cases of Cancer 
1 92.66% 
2 6.93% 
3 0.41% 
Gender 
Female 36.92% 
Male 63.08% 
 
4.4.2. Medical and Drug Events and Costs  
In order to calculate the overall cost for each treatment arm, the event rates needed to be 
quantified and multiplied by their respective costs. Four general costs were reported and 
used in the cost-effectiveness model: protocol costs, adverse event costs, background 
treatment costs, and progression costs. The protocol, adverse, and background treatment 
costs pertain to the progression-free health state, while the progression events pertain to 
the progression health state. Expected protocol costs and adverse event costs were 
evaluated by multiplying the expected rate of events per one month period by the average 
cost per event. Background treatment and progression costs were evaluated directly from 
Ontario hospital records from the identified cohort of interest.  
 
4.4.2.1. Protocol Events  
Protocol events are all events that were specified within the AVAglio and RTOG 0825 
protocols; this includes radiation and chemotherapy [17, 64]. As the survival curves used 
to estimate the transition probabilities used in the model were weighted to their respective 
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population sizes, so too were protocol events; a total of 1,542 patients participated: 921 
from the AVAglio study and 621 from the RTOG 0825 study [16, 17].  
 
The AVAglio study followed the following treatment regimen (Figure 20), split into three 
phases [64]:  
1. The first phase termed the concurrent phase starts between 28 and 49 days since 
debulking surgery or biopsy. In the SOC arm, patients are treated with radiation 
therapy five days per week for six weeks concomitant with 75 mg/m
2 
of body 
surface area TMZ
 
once a day. The BEV plus the SOC arm adds 10 mg/kg of BEV 
every two weeks concomitant with the SOC arm.  
 
2. The second phase termed the maintenance phase follows a four week treatment 
break. In the SOC arm, patients receive six cycles of 150 mg/m
2 
TMZ once a day, 
five days per week followed by a 23 day break. The BEV plus the SOC arm adds 
10 mg/kg or BEV every two weeks concomitant with the SOC arm. 
 
 
3. The third phase termed the monotherapy phase only applies to the BEV plus the 
SOC arm where patients receive 15mg/kg BEV every three weeks until tumor 
progression. 
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Tumor debulking surgery or biopsy 
RT – 5 day per week, for 6 weeks  
TMZ – 75 mg/m
2
 daily, for 6 weeks 
BEV/Placebo – 10 mg/kg every 2 weeks, for 6 weeks 
28-49 Day Break 
4 Week Break 
TMZ – 150 mg/m
2
 for 5 days followed by a 23 day break, for 6 cycles 
BEV/Placebo – 10 mg/kg every 2 weeks over a 28 day period, for 6 cycles 
BEV/Placebo – 15 mg/kg every 3 weeks until progression 
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Figure 20. AVAglio treatment regiment 
 
The RTOG 0825 protocol is split into two treatment phases (Figure 21): 
1. The first phase, termed the concurrent phase, started between 21 and 35 days after 
surgery. In the SOC arm, radiation therapy is administered five days per week for 
six weeks. TMZ is administered at 75mg/m
2
 of body surface area per day for six 
weeks. In the BEV plus the SOC arm, BEV is administered at 10 mg/kg every 
two weeks starting at week four of radiotherapy, concomitant with the SOC arm.  
52 
 
Tumor debulking surgery  
RT – 5 day per week, for 6 weeks  
TMZ – 75 mg/m
2
 daily, for 6 weeks 
BEV/Placebo – 10 mg/kg every 2 weeks, starting on week 4 
21-35 Day Break 
4 Week Break 
TMZ – 150 mg/m
2
 for 5 days followed by a 23 day break, for 12 cycles 
BEV/Placebo – 10 mg/kg every 2 weeks over a 28 day period, for 12 cycles 
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2. The second phase termed the maintenance phase follows a 28 days treatment 
break. In the SOC arm, 12 cycles of TMZ is administered at 150 mg/m
2
 five days 
per week followed by 23 days of no TMZ treatment. In the BEV plus the SOC 
arm, 10 mg/kg of BEV is administered every two weeks concomitant with the 
SOC arm.  
Figure 21. RTOG 0825 treatment regimen  
 
As reported in the patient-level Ontario medical records, an average weight of 77.25 kg 
and an average height of 168.92 cm was used to calculate BEV plus TMZ dosing (Table 
10). This weight is similar to weights used in other GBM cost-effectiveness studies [96]. 
The Mosteller equation was used to calculate the body surface area for TMZ dosing 
[109].  
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Table 10. Biological parameters used to calculate TMZ and BEV dosing 
Biological parameter Mean Std. Deviation 
Height (cm) 168.9233 8.2931 
Weight (kg) 77.2527 16.5020 
 
4.4.2.2. Protocol Costs  
Protocol costs were composed of either baseline debulking surgery or biopsy, radiation 
therapy or chemotherapy. Costs were identified from the Ontario health records using 
Canadian Classification of Health Intervention (CCI) codes. These codes were used by 
hospitals to record the procedures that were administered to the patients. A list of CCI 
codes used to identify procedures can be found in the appendix (Appendix). BEV plus 
TMZ costs were calculated using health records: the cost of BEV was calculated by 
multiplying the mean weight by the cost per kg; the cost of TMZ was calculated by 
multiplying the milliliter per body surface area by the body surface area, (height (cm) x 
weight (kg)/3600)
½
, multiplied by the cost per milliliter. All protocol costs are reported in 
Table 11.  
 
4.4.2.3. Adverse Events 
Both the AVAglio and RTOG 0825 clinical trials reported progression free adverse event 
frequencies for both arms. As no BEV was administered to Ontario patients, real-world 
event rates could not be used to populate the BEV plus the SOC arms of this study. 
Therefore, the real-world SOC arm adverse event rate distribution was calculated using 
data from Ontario health records, and adjusted for the BEV plus the SOC arm using the 
AVAglio and RTOG 0825 reported event probabilities. The reported AE probabilities in 
the AVAglio and RTOG 0825 trials were assumed to remain constant over the trial 
period, and converted into rates to estimate the BEV AE rates using Equation 3 [108].  
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Equation 3. Formula used to calculate the probability of a adverse event occurring per 
period time  
𝑝 = 1 − 𝑒−𝑟𝑡           (3) 
A full list of reported adverse events, relative risks, and their respective OHIP and 
International Classification of Disease version 10 (ICD-10) diagnosis codes are reported 
in the appendix (Appendix). 
 
4.4.2.4. Adverse Event Costs 
Similar to protocol costs, an AE cost was calculated from the Ontario health records 
using OHIP and ICD-10 diagnosis codes. A full list of reported AEs and their respective 
OHIP, and ICD-10 diagnosis codes are reported in the appendix (Appendix). 
 
4.4.2.5. Background Treatment Costs 
Background treatment events are defined as all recorded medical events that are not 
classified as protocol events or AEs. As the AVAglio and RTOG 0825 clinical trials did 
not report differences in events not classified as AEs, this study assumed the background 
event costs is the same for the two treatment arms. Average background treatment costs 
were extracted from Ontario health records and used in the study. 
 
4.4.2.6. Progression Costs 
Once a patient progresses from the progression free to the progression health state, 
patients in both treatment and SOC arms in the AVAglio and RTOG 0825 clinical trials 
had the opportunity to cross arms. However, the number of patents crossing over, their 
treatment regimens, and event distributions were not reported. Therefore, it is difficult to 
accurately model the incurred costs to reflect the AVAglio and RTOG 0825 RCTs within 
the progression state. So, progression event distributions were extracted from all patients 
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who were deemed to have progressed from the progression free state in the Ontario health 
records.  
 
As the Ontario health records are administrative, and therefore do not record tumor 
progression, a patient was assumed to be in the progression state if they did not receive 
TMZ for greater than five weeks after they started TMZ. A greater than five week gap 
was chosen because the longest period where a patient could have a TMZ treatment gap 
would be the four week treatment break between the concurrent and maintenance phase. 
Moreover, due to the severity of GBM and the amount of medical treatment a patient 
would receive, it was assumed that a GBM patient would be compliant to treatment 
guidelines.  
 
A Canadian survey on newly diagnosed GBM treatment practice has shown that 56% of 
respondents use in-house or center specific treatment guidelines with 64% of respondents 
using a one phase approach [110]. This means that concurrent RT and TMZ use will be 
highly correlated in the administrative records. The maintenance phase, which consists 
only of TMZ therapy, would not be practiced by those physicians using a one phase 
approach. Two scenarios are therefore possible in practice: a monotherapy phase is not 
used and therefore not reflected in the administrative records, or a monotherapy phase is 
used and therefore reflected in the administrative records. As TMZ is correlated with RT 
use, in the one phased approach, lack of TMZ would indicate the patient entered the 
progression state as they have failed on TMZ. In the second scenario, a monotherapy 
phase is used, a gap in TMZ use would indicate a patient is either taking a four week 
break before starting monotherapy or they have entered the progression state and are not 
receiving TMZ. As we used a five week gap threshold of no TMZ use, we can establish 
that the patient is not taking a break before starting monotherapy, rather has entered the 
progression state as they have failed on TMZ. All costs incurred after the five week TMZ 
gap should therefore be incurred in the progression state. We chose not to use RT 
cessation as an indicator of entering the progression state, as this indicator would not 
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correctly classify patients who stopped receiving RT due to a monotherapy phase of 
treatment. A five week gap in TMZ could be too short and a patient could be on a five or 
six week treatment break before starting their monotherapy phase. This should not be a 
challenge as a single phased approach is used by the majority of Canadian oncologists 
and the majority of administrative records should not exhibit a significant treatment 
break. For those Canadian oncologists who do use a monotherapy phase, we assumed that 
their guidelines would be similar to both the RTOG 0825 and AVAglio treatment 
guidelines. Therefore, a five week TMZ treatment gap should not overstate the number of 
patients progressing into the progression state early in their treatment and not run the risk 
of incurring progression free state costs in the progression state.  
 
4.4.3. Model Medical and Drug Costs 
Table 11. Costs used in base scenario for cost-effectiveness model 
Cost Group Cost Mean Source 
Protocol Cost Excision/Biopsy $16,098.1500 DAD/NACRS 
Pharmacotherapy 
Administration 
$1,406.5500 DAD/NACRS 
Radiation $642.9356 DAD/NACRS 
TMZ ($/mg)* $1.5869 ODB 
BEV ($/kg)* $25.0231 NDFP 
Adverse Event Cost Abscesses Fistulae $444.8700 OHIP/DAD/NACRS 
Anemia $609.3700 OHIP/DAD/NACRS 
Arterial Thromboembolic 
Events 
$7,461.8800 OHIP/DAD/NACRS 
Cerebral Hemorrhage $6,003.9200 OHIP/DAD/NACRS 
Congestive Heart Failure $99.4900 OHIP/DAD/NACRS 
Fatigue $1,272.7300 OHIP/DAD/NACRS 
Gastrointestinal 
Perforation 
$444.8700 OHIP/DAD/NACRS 
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Table 12 Continued. Costs used in base scenario for cost-effectiveness model 
Cost Group Continued Cost Mean Source 
Adverse Event Cost 
Continued  
Hemorrhage $610.7000 OHIP/DAD/NACRS 
Hypertension $42.8500 OHIP/DAD/NACRS 
Leukopenia $4,265.1600 OHIP/DAD/NACRS 
Lymphopenia $36.8100 OHIP/DAD/NACRS 
Mucocutaneous Bleeding $97.7500 OHIP/DAD/NACRS 
Nausea and Vomiting $864.4000 OHIP/DAD/NACRS 
Neutropenia $4,265.1600 OHIP/DAD/NACRS 
Proteinuria $38.0500 OHIP/DAD/NACRS 
Thrombocytopenia $98.4500 OHIP/DAD/NACRS 
Thromboembolic Disease $921.4400 OHIP/DAD/NACRS 
Venous Thromboembolic 
Events 
$77.5200 OHIP/DAD/NACRS 
Visceral Perforation $58.5000 OHIP/DAD/NACRS 
Wound Healing 
Complications/ Wound 
Dehiscence 
$68.0700 OHIP/DAD/NACRS 
Background Medical 
Cost 
 Varying by 
month 
OHIP/DAD/NACRS 
Progression Costs  Varying by 
month 
OHIP/DAD/NACRS 
*Note: As reported in the NDFP and ODB units. BEV cost $5.0000/ mg. 
 
4.5. Discounting 
An annual 5% discount rate was applied to the model in accordance with the Canadian 
Agency for Drugs and Technologies in Health recommendations [111, 112] . However, 
0% and 3% discounting rates were considered. 
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4.6. Health Utilities 
Health utility values were gathered from a study by Garside et al.  [44], which evaluated 
the cost-effectiveness of carmustine implants and TMZ in newly diagnosed GBM. As the 
AVAglio and RTOG 0825 clinical trials report conflicting QoL measures between BEV 
plus TMZ patients, this study assumed that the two treatment arms experience the same 
QALY and QALY progression over their treatment. The mean QALY was used for this 
study; all QALYs used for this study are reported in Table 13.  
 
Table 13. QALY estimates used in base scenario for cost-effectiveness model 
Scenario Mean QALY Median 
QALY 
QALY Std. 
Dev 
PFS + concurrent treatment phase 0.7426 0.7875 0.2021 
PFS + maintenance/ monotherapy phase 0.7331 0.7750 0.1991 
Progression state 0.7314 0.7750 0.2067 
 
4.7. Sensitivity Analysis 
4.7.1. Deterministic Sensitivity Analysis 
Deterministic sensitivity analysis (DSA) was performed on all transition probabilities, 
health utility values, and costs. Transition probabilities and health utility values were 
varied by ±5% to a maximum of 100% and a minimum of 0% (Table 14); costs were 
varied by ±20% (Figure 15). The DSA was performed by varying each utility and cost 
point estimate by their respective percentage amount, and recalculating the ICUR to 
evaluate the differential effect. 
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As the survival curves for each treatment arm was projected to a five year horizon, 
sensitivity was performed on the projection by altering the survival slope past the 30 
month of RCT determined survival. Rather than projecting forward using the best fit 
model, a constant slope was implemented.  
 
Table 14. Deterministic Sensitivity Model QoL Utilities 
Scenario High QALY(+5%) Low QALY (-5%) 
PFS + concurrent treatment phase 0.7797 0.7055 
PFS + maintenance/ monotherapy phase 0.7698 0.6964 
Progression state 0.7680 0.6948 
 
Table 15. Deterministic Sensitivity Model Costs  
 Cost Group Cost High (+20%) Low (-20%) 
Protocol Cost Excision/Biopsy $19,317.7800 $12,878.5200 
Pharmacotherapy Administration $1,687.8600 $1,125.2400 
Radiation $771.5227 $514.3485 
TMZ ($/mg) $1.9043 $1.2695 
BEV ($/kg) $30.0277 $20.0185 
Adverse Event Cost Abscesses Fistulae $533.8440 $355.8960 
Anemia $731.2440 $487.4960 
Arterial Thromboembolic Events $8,954.2560 $5,969.5040 
Cerebral Hemorrhage $7,204.7040 $4,803.1360 
Congestive Heart Failure $119.3880 $79.5920 
Fatigue $1,527.2760 $1,018.1840 
Gastrointestinal Perforation $533.8440 $355.8960 
Hemorrhage $732.8400 $488.5600 
Hypertension $51.4200 $34.2800 
Leukopenia $5,118.1920 $3,412.1280 
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Table 16 Continued. Deterministic Sensitivity Model Costs  
Cost Group Cost High (+20%) Low (-20%) 
Adverse Event Cost 
Continued 
Lymphopenia $44.1720 $29.4480 
Mucocutaneous Bleeding $117.3000 $78.2000 
Nausea and Vomiting $1,037.2800 $691.5200 
Neutropenia $5,118.1920 $3,412.1280 
Proteinuria $45.6600 $30.4400 
Thrombocytopenia $118.1400 $78.7600 
Thromboembolic Disease $1,105.7280 $737.1520 
Venous Thromboembolic Events $93.0240 $62.0160 
Visceral Perforation $70.2000 $46.8000 
Wound Complications/ Dehiscence $81.6840 $54.4560 
Background 
Medical Cost 
Varying by month   
Progression Costs Varying by month   
 
4.7.2. Probabilistic Sensitivity Analysis 
Probabilistic sensitivity analysis (PSA) was also performed on all transition probabilities, 
health utility values, and costs. A beta distribution was fit to transition probabilities and 
health utility values (Table 17), while a lognormal distribution was used for costs (Table 
18) [113]. PSA utility and cost estimates were entered into the cost-effectiveness model 
by substituting the point estimates used in the base case model with the appropriate utility 
and cost distributions. A 1000 iteration Monte Carlo simulation was performed, sampling 
from independent distributions within each iteration.  
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Table 17. PSA Model QoL Utilities 
Scenario Alpha Beta 
PFS + concurrent treatment phase 120.8911 41.9033 
PFS + maintenance/ monotherapy phase 125.9155 45.8421 
Progression state 116.9758 42.9583 
 
Table 18. PSA Model Costs 
Cost Group Cost Mean (Ln) Std Dev (Ln) 
Protocol Cost Excision/Biopsy $9.4483 $0.5719 
Pharmacotherapy 
Administration 
$6.6029 $0.7602 
Radiation $6.0033 $0.7590 
TMZ ($/mg) $0.4160 $0.7596 
BEV ($/kg) $3.2160 $0.0856 
Adverse Event Cost Abscesses Fistulae $6.0180 $0.5725 
Anemia $3.8753 $1.7540 
Arterial Thromboembolic 
Events 
$8.0144 $1.6024 
Cerebral Hemorrhage $7.6654 $1.5981 
Congestive Heart Failure $3.9642 $1.1148 
Fatigue $6.0917 $1.2942 
Gastrointestinal Perforation $6.0180 $0.5725 
Hemorrhage $4.0717 $1.7339 
Hypertension $3.4712 $0.6751 
Leukopenia $4.6773 $2.7228 
Lymphopenia $3.3297 $0.7990 
Mucocutaneous Bleeding $3.8237 $1.1487 
Nausea and Vomiting $6.0680 $1.5269 
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Table 19 Continued. PSA Model Costs 
Cost Group Cost Mean (Ln) Std Dev (Ln) 
Adverse Event Cost 
Continued 
Neutropenia $4.6773 $2.7228 
Proteinuria $3.6389 $0.0001 
Thrombocytopenia $4.0696 $0.9901 
Thromboembolic Disease $4.2847 $1.9706 
Venous Thromboembolic 
Events 
$3.8035 $1.4263 
Visceral Perforation $3.8559 $0.7119 
Wound Healing Complications/ 
Wound Dehiscence 
$3.8815 $0.7643 
Background Medical 
Cost 
Varying by month   
Progression Costs Varying by month   
 
4.8. Software 
Digitizeit was used to digitize the plotted points on the AVAglio and RTOG 0825 
Kaplan-Meier curves [114]. R v3.1 was used to analyze the individual AVaglio and 
RTOG 0825 Kaplan-Meier curves and estimate the pooled Kaplan-Meier curves [115-
120]. Excel 2010 was used to calculate transition probabilities from the pooled Kaplan-
Meier curves [121]. SAS v9.3 was used to analyze the Ontario healthcare datasets and 
estimate costs [122]. TreeAge Pro 2011 was used to construct the economic impact 
model [97]. 
63 
 
Chapter 5 
5. Results 
5.1. Base Case Cost Effectiveness of Bevacizumab 
The cumulative expected cost from the public payer’s perspective over a five year period 
for BEV plus the SOC is $632,602, while the cumulative expected cost of the SOC alone 
is $199,284. The cumulative expected QALY over a five year period for BEV plus the 
SOC is 1.16 QALY, while the cumulative expected QALY for the SOC is 1.11 QALY. 
As costs and utility values are the same for the progression state in both the SOC and 
SOC and BEV arms, the incremental costs and QALY is due to the increased time spent 
in the progression free state the additional costs for BEV for the SOC and BEV arm 
compared to the SOC arm. The expected ICUR for BEV plus the SOC compared to the 
SOC alone is $8,393,212 per QALY. As can be seen in Table 20, the majority of the costs 
in both arms are incurred within the first 12 months of treatment.  
 
As both the AVAglio and RTOG 0825 RCTs contributed a minimum of 30 month of 
survival data, the ICER at 30 months and five years were compared to establish the effect 
of projecting the survival estimates. Figure 22 graphically displays the ICER between 
BEV and SOC compared to SOC for each month since treatment initiation. At 30 months, 
the ICER was $6,189,191 compared to the base case five year ICUR of $8,393,212. 
While the ICUR was higher for the five year mark, the 30-month ICUR was similarly 
high. Therefore, projecting the survival curves did not influence the ICUR towards a cost-
effective BEV plus SOC result. Moreover, the ICUR remained at similar levels from 18 
months on wards indicating that projecting survival resulted in similar ICURs as would 
be calculated at several points within the RCT survival data.  
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Table 20. Cumulative mean cost and QALY for the BEV plus the SOC treatment arm and 
SOC treatment arm by treatment month 
 SOC BEV plus SOC ICUR 
Months 
Since 
Diagnosis 
Cum. Exp. 
Cost 
Cum. Exp. 
QALY 
Cum. 
Exp. Cost 
Cum. Exp. 
QALY 
ICUR If Time 
Horizon Ended Here 
1 $39,541 0.03 $49,917 0.03 - 
6 $136,843 0.32 $338,698 0.33 $26,594,590 
12 $181,537 0.60 $566,435 0.63 $13,810,726 
18 $192,096 0.78 $623,161 0.83 $8,509,066 
24 $194,403 0.90 $628,627 0.96 $6,670,973 
30 $196,002 0.97 $630,274 1.04 $6,189,191 
36 $197,174 1.02 $631,345 1.09 $6,194,425 
42 $197,917 1.06 $631,891 1.12 $6,562,069 
48 $198,493 1.08 $632,235 1.14 $7,115,435 
54 $198,956 1.10 $632,467 1.15 $7,762,653 
60 $199,284 1.11 $632,602 1.16 $8,393,212 
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Figure 22. Expected ICUR between BEV plus the SOC compared to the SOC for the first 
five years from diagnosis of newly diagnosed GBM 
 
5.1.1. Incurred Costs per Month  
Monthly state-specific costs were estimated for each treatment arm, BEV plus the SOC 
and the SOC. The total majority of costs are incurred within the progression free state for 
both the BEV plus the SOC treatment arm (Figure 23) and the SOC treatment arm 
(Figure 24). Compared to the progression free arm, low amounts of expected costs are 
incurred in the progression arm for both treatment arms. A graphical summary of costs 
may appear jagged within the first six weeks of treatment as large cost items – such as 
BEV – are modeled to be administered using both the AVAglio and RTOG 0825 
regimens. The two regimens outlining BEV dosing, the first from the AVAglio and the 
second from the RTOG 0825 trial, call for differing timing in BEV administration, and 
the model is a summation of the two regimes; when BEV is administered at staggered 
time points, the total costs appear to be smooth. However, when the regimens’ time 
points align in BEV dosing, the total costs appears to be jagged, such as at the cost point 
for two months since GBM diagnosis. 
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Figure 23. Expected monthly costs by health state to treat GBM with BEV plus the SOC 
 
 
Figure 24. Expected monthly costs by health state to treat GBM with the SOC 
 
Between Figure 23 and Figure 24, the difference in expected costs within the progression 
free state is mostly due to the cost of BEV therapy. As one can see, the costs incurred in 
the BEV and SOC progression free arm are incurred at a later month since GBM 
diagnosis as compared to the SOC arm, which reflects the increased duration patients 
remain the progression free state when treated with BEV and the SOC. The progression 
costs are quite low comparatively to progression free state as treatment is not continued. 
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The two arms are quite similar in progression costs as this study assumed the same 
monthly cost.  
 
5.1.2. Expected Value of Perfect Information 
Using an expected Canadian annual GBM population of 354 patients  [123], discounted 
at 5% over a 10 year period, the population expected value of perfect information at the 
calculated ICUR of $8,393,212 per QALY is $5,485,641,778. However, at the WTP used 
for this study, $132,264, the value of perfect information is $4,271, which indicates that it 
is not worth conducting further research in BEV plus the SOC for GBM as the returns 
will not justify the research costs.  
 
5.2. Deterministic Sensitivity Analysis 
5.2.1. One-Way Deterministic Sensitivity Analysis  
One-way sensitivity analysis was performed on model inputs that were specific to BEV 
plus the SOC (Table 21). Altering the probability of remaining in progression free state 
had the largest effect on ICUR as compared to all costs and QoL metrics. Decreasing the 
probability of remaining in the PFS state by 5% resulted in a -$1,223,601 per QALY 
while increasing the progression free state transition probability by 5% resulted in an 
$853,904 per QALY ICUR. The negative ICUR resulting from a 5% decrease in the 
progression free state transition probabilities is due to a resulting negative incremental 
utility.  
 
Following the transition probabilities, QoL metrics had the second largest impact on 
ICUR. Decreasing the BEV plus the SOC arm progression free state utility by 5% 
resulted in a $44,537,392 per QALY ICUR, while increasing the progression free state 
utility by 5% resulted in a 4,633,174 per QALY ICUR. A small change in ICUR was 
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observed when adjusting costs by ±20%. Altering the drug costs of BEV resulted in the 
largest changes in ICUR. A decrease in BEV cost by 20% resulted in a $6,964,463 per 
QALY, while increasing BEV costs by 20% resulted in a $9,821,961 per QALY.  
 
Table 21. Deterministic sensitivity for BEV plus the SOC arm inputs on the resulting 
ICUR  
Category Low High 
Base Case $8,393,212 
BEV AE Costs $8,390,094 $8,396,330 
BEV Background Costs $8,323,902 $8,462,522 
BEV Drug Costs $6,964,463 $9,821,961 
BEV Progression Free to Progression Free 
Transition Probability 
-$1,223,601 $853,904 
BEV Progression to Progression Transition 
Probability 
$13,339,946 $6,044,459 
BEV QoL $44,537,392 $4,633,174 
 
Decomposing the ICUR into its incremental effectiveness and incremental cost 
components, one can see that lowering the probability of remaining in the progression 
free state by 5%, in the BEV plus the SOC arm, strongly affects the incremental 
effectiveness. By lowering the probability by 5%, the patients receiving BEV plus the 
SOC remain in the progression free state for a shorter period than the SOC arm, therefore 
reducing the treatment’s effectiveness and resulting in a negative incremental 
effectiveness, -0.2345. Similarly, altering the QoL of those receiving BEV plus the SOC 
had a large effect on the incremental effectiveness. Decreasing the progression free state 
utility by 5% reduces the incremental effectiveness to 0.0097 QALY.  
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Similarly, the incremental cost component of the ICUR is heavily affected altering the 
probability of remaining in the progression free state. Decreasing the probability of 
remaining in the progression free state by 5% decreases the incremental costs to 
$286,892, while increasing the probability by 5% increases the incremental costs to 
$586,967. The second largest impact on incremental costs is caused by the drug cost of 
BEV. Decreasing the drug costs of BEV by 20% decreases the incremental cost to 
$359,556. Increasing the drug costs of BEV by 20% increase the incremental costs to 
$507,081.  
 
Each protocol cost component was investigated for its impact on the overall costs on the 
five year ICER by changing each cost component to zero cost and calculating the ICER 
(Table 22). As one can see, the difference in ICER is nominal if present. As all patients 
require an excision or biopsy, then, as expected, the ICER without the excision or biopsy 
cost remains the same as the base case. 
 
Table 22. One way sensitivity on protocol cost components for their effect on the ICER 
Cost Group Cost Component ICER 
Base Case  $8,393,212 
Protocol Cost Excision/Biopsy $8,393,212 
Pharmacotherapy 
Administration 
$7,908,078 
Radiation $8,391,432 
 
As the survival curves were projected to a five year horizon, sensitivity was performed on 
the effect of the projection method. While the best fit projected curve at the five year 
horizon resulted in an estimated ICUR of $8,393,212 per QALY, a constant slope after 30 
months – last month of RCT contributed survival data – resulted in an estimated ICUR of 
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$10,545,883 per QALY. While the best fit projected ICUR is lower than the constant 
slope ICUR, neither were cost-effective.  
 
5.3. Probabilistic Sensitivity Analysis 
For the probabilistic sensitivity analysis, all distributions were simultaneously sampled. 
The expected cumulative cost and QALY for the BEV plus the SOC is $633,318 and 1.14 
QALY. The expected cumulative costs and QALY for the SOC arm is $206,501 and 1.12 
QALY. The expected ICER comparing the two arms is 421,340,850 per QALY. The 
difference between the base case and the expected probabilistic sensitivity ICUR is due to 
the small difference in QALY. As the incremental difference between the two arms is 
already small, any changes in difference will have exponential effects on the ICUR.  
 
The incremental cost-effectiveness scatter plot was constructed from 1000 simulation 
results (Figure 25). The plot compared BEV plus the SOC to the SOC arms. The majority 
of simulations (65.8%) resulted in a positive incremental effectiveness however, a 
considerable number of trials experienced negative effects by receiving BEV plus the 
SOC. Overall, BEV plus the SOC was well outside the willingness to pay (WTP) of 
$132,264, and could not be justified as a cost-effective first line treatment for GBM.  
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Figure 25. Probabilistic scatter plot of incremental cost-effectiveness of BEV plus the 
SOC compared to the SOC 
 
A cost-effectiveness acceptability curve (CEAC) was constructed to identify the 
percentage of simulated ICUR values would meet the WTP when varying the WTP value 
(Figure 26) [108, 113, 124]. Even at a WTP of $250,000 per QALY, none of the BEV 
plus the SOC arm simulations were cost-effective. At a WTP threshold of $4,000,000 per 
QALY, a few simulations of BEV plus the SOC become cost-effective.  
 
Figure 26. Probability that BEV plus the SOC or the SOC are cost-effective with variable 
WTP 
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Chapter 6 
6. Discussion & Conclusions 
6.1. Summary 
This study modeled the treatment for first -line GBM using a Markov model with three 
states: progression free, progression, and death. This model was designed after clinical 
practice and clinical trial reported outcomes. Three general inputs were used to populate 
the model: survival probabilities, costs, and QoL metrics.  
 
The survival probabilities derived from two clinical trials, the AVAglio and RTOG 0825 
RCTs, where published survival curves were combined to determine the pooled survival 
curves [16, 17]. To avoid relying on the Cox-proportional hazards assumption, the 
survival outcomes from the trials were reverse engineered and combined into a single 
survival curve. A parametric model was applied to the curve to project the survival 
probabilities past the clinical trial’s duration. Probabilities from the clinical trials were 
used until 30 months, after which probabilities of survival were estimated from the 
parametric models.  
 
Cost were estimated from both the clinical trial data and Ontario health records. The 
event rates for the SOC arm were derived from Ontario health records, however, as no 
patient in Ontario has received BEV plus the SOC for first line GBM therapy, clinical 
trial data was used to estimate the BEV plus the SOC arm event rates. Costs for each 
event were extracted from the Ontario health records. In Ontario, ODB has issued a 
limited use code for TMZ reimbursement. This indicates that TMZ can only be used for 
certain indications. While TMZ is explicitly not funded for metastatic melanoma, it has 
complete public funding for newly diagnosed GBM, along with other brain cancer 
indications. Therefore, the health records used to elicit the cost of TMZ would properly 
capture its cost.  
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Both the AVAglio and RTOG 0825 clinical trials investigated the effect of BEV plus the 
SOC on QoL metrics. However, the results from each trial conflicted. Therefore, the 
same QoL metrics were used in both arms. These metrics were estimated using scenarios 
from GBM patients by a panel familiarized with the Standard Gamble method  [44].  
 
The base case found that BEV plus the SOC for first-line GBM therapy had an 
incremental cost-effectiveness ratio of $8,393,212 per QALY. The largest component of 
the incremental cost was BEV drug costs.  
 
From deterministic sensitivity analysis, the most sensitive parameter in calculating the 
ICUR is the probability to remain in the progression free state. Following, is the QoL 
metric, which also had a material impact on the expected ICUR. With respect to costs, the 
ICUR was most sensitive to the drug costs of BEV. Probabilistic sensitivity showed that 
at current treatment costs and effectiveness, the WTP threshold would need to be very 
high to find BEV plus the SOC cost-effective.  
 
6.2. Discussion 
From this analysis we can conclude that BEV plus the SOC is not cost-effective as a first-
line therapy for GBM when compared to the SOC alone. In Ontario, no patients received 
BEV for first-line therapy, however, it is prescribed as a salvage or second-line treatment.  
 
In general, there are three ways to show cost-effectiveness: increase QoL, increase 
survival, or decrease costs. The hope was that either overall survival was increased by 
BEV plus the SOC, or that as progression free survival is increased, and that QoL is 
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higher in the progression free state. Therefore, the overall QoL for BEV would outweigh 
the cost and show a cost-effective alternative to the SOC. Two large multicenter RCTs 
investigated the use of BEV plus the SOC as a first-line treatment, with evidence 
surfacing that progression free survival is increased. Unfortunately for patients, both 
clinical trials did not show an overall survival benefit. Moreover, the mild increase in 
QoL due to a longer progression free survival, did not outweigh the incremental costs. 
Even so, the QoL of patients on BEV plus the SOC is currently in question as the two 
RCTs investigating BEV found conflicting evidence on the treatment’s QoL effect.  
 
Going forward, future research on the QoL of patients receiving BEV plus the SOC is 
necessary to determine if overall QoL is increased or decreased. As the ICUR is sensitive 
to QoL, it is feasible that BEV plus the SOC can be cost-effective. This however, would 
require general consensus of the metrics and methods used to measure QoL. Once agreed 
upon, a utility value can be estimated.  
 
It should be noted that Japan has added BEV and SOC to its SOC for newly diagnosed 
GBM [125]. The health authorities of Japan made this decision as they recognized the 
benefit of a longer progression free state and the possible increase in QoL for those on 
BEV and the SOC.  
 
The simple solution towards proving cost-effectiveness would be to decrease the costs of 
BEV. Lowering the price of the drug, however, would not occur as BEV is currently used 
as a first-line treatment in metastatic colorectal cancer, and an option for locally advanced 
metastatic or recurrent non-small cell lung cancer, and platinum-sensitive recurrent 
epithelial ovarian, fallopian tube, and primary peritoneal cancer [69]. If the manufacture 
of BEV were to lower their selling price of BEV, they would forgo the revenue generated 
from the other indications, for the smaller GBM indication. To achieve drug coverage for 
BEV while maintaining the manufacturer’s revenue stream, drug insurers, such as ODB, 
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and the manufacturer can engage in a product listing agreement (PLA). PLAs are 
confidential purchasing agreements between payer and drug manufacturers outlining the 
reimbursed price of a drug for a specific indication, line-of-therapy, or duration [126]. 
 
However, it should be noted that no phase 1 clinical trials were performed for BEV plus 
the SOC in first-line GBM treatment. The optimal dose of a drug is determined in part by 
a phase 1 RCT. Currently, dosing is determined by prior experience  [17] and therefore, it 
is possible that the dose required to treat GBM with BEV plus the SOC can be reduced, 
thereby reducing the overall costs. Moreover, it is conceivable that reducing the dosing of 
BEV will have an effect on reducing the AEs. This would not only decrease the costs 
associated with the AEs, but could increase the QoL.  
 
Future research on genetic markers that correlate with a positive and significant 
improvement in survival when identified and treated with BEV and the SOC could be 
used to show cost-effectiveness of the new treatment and increase QoL. Currently, all 
genetic markers tested in the AVAglio and RTOG 0825 trials did not correlate with better 
survival for patients receiving BEV and the SOC compared to the SOC  [16, 17].  
 
Overall, BEV plus the SOC is not cost-effective for first-line GBM. However, further 
research is required on the QoL for those on the treatment and the optimal dosing, which 
can influence the ICUR and show cost-effectiveness. Effort, though, should be placed on 
increasing the survival of GBM patients, such as identifying genetic markers that 
correlate with better prognostic outcomes, as no major increase in survival due to 
treatment has occurred since the approval of TMZ for GBM.  
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6.3. Strengths 
To our knowledge, this is the first study on the cost-effectiveness of BEV plus the SOC 
where both clinical trial results are incorporated and real-world costs and distributions are 
used. A prior study was recently published modeling the cost-effectiveness of BEV plus 
the SOC compared to SOC for first-line GBM therapy [123]. This study only used the 
AVAglio study, assumed proportional hazards, and drew its costs from published 
sources. While all these values were stated in the publication and are valid, this study 
builds upon prior work by incorporating both the AVAglio and RTOG 0825 clinical trial 
results and reverse engineering the survival curves to find the survival of both studies 
together thereby avoiding the Cox-proportional hazards assumption.  
 
Moreover, the prior study assumed a uniform probability of AEs. While also valid, it has 
been shown that the majority of costs are incurred near diagnosis and death [127]. As the 
median survival for those diagnosed with GBM is not very long and the AEs are quite 
rare, the assumption of uniform AEs may not have a large impact. However, this study 
incorporates real-world AE distributions, which occur mostly near diagnosis when the 
majority of patients are alive. This increases the accuracy of incurred costs due to AEs.  
 
Another study strength is that costs and their distributions are those observed in real-
world Ontario practice. As opposed to using costs from a literature search, this study 
implemented inclusion and exclusion criteria that mirrored those from the published 
RCTs. Therefore, costs should be similar with those published in cost-effectiveness 
studies run in parallel with an RCT.  
 
The largest discrepancy between the inputs of the prior study and this study are the drug 
costs of BEV. The published study used BEV costs from IMS Brogan [128]. These costs 
seem to differ from those found in the Ontario NDFP database. When the BEV costs 
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from the prior study are used in lieu of the NDFP BEV costs, the model used for this 
study produced an expected ICUR that is very similar to the prior study’s ICUR – 
$680,533 per QALY vs. $607,966 per QALY. The benefit of using the NDFP prices is 
that these are costs incurred from the Ontario healthcare perspective as opposed to relying 
on the official list prices, which are not necessarily incurred by the Ontario healthcare 
system.  
 
6.4. Limitations 
We recognize that there are several limitations to this study. From our perspective, the 
largest limitation to this study is that no Ontario patient has received BEV plus the SOC 
for first-line GBM. Therefore, the survival and AE distributions are derived from RCT 
proxy sources. While RCTs are an excellent source for survival probabilities, they may 
not represent real-world treatment patterns. Rather, patients in RCTs may be under 
increased observation, and, as a consequence, receive improved healthcare. This could 
increase the survival time of a patient within a RCT compared to real-world survival. The 
effect on this study may be that the median survival is longer than what would be 
observed in the real-world. However, this method is commonly used in cost-effectiveness 
analysis as there a few, or sometimes no, alternatives available and a decision on whether 
to add a therapy to the SOC needs to be made [123, 129, 130].  
 
As real-world data is not available for the BEV and SOC arm, fatal AEs may not be 
properly captured and incorporated into this study. A paper published by Wu et al. found, 
using a meta-analysis, that BEV in cancer patients was statistically associated with 
increased fatal AEs [131]. The publication noted that the use of taxanes or platinum with 
BEV showed stronger association with the fatal AEs. As BEV is not used to treat newly 
diagnosed GBM in the real-world, the AEs, fatalities, and costs associated were not 
directly captured in this study. However, some of these costs should be incorporated into 
this study. If a patient died during the RTOG 0825 and AVAglio trials from BEV, it 
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would have been captured in the overall survival and reflected in this analysis in the 
survival, cost, and QALY metrics. Additionally, all AEs from the RCTs were quantified 
and dollarized; therefore, if the BEV arm had more AEs, then the increase would be 
captured and included in this study in the cost metrics.  
 
Additionally, because this study used published survival curves, the survival estimates 
could only span as long as those published. In order to extend the study’s timespan, a 
parametric curve was fit to the published curves and converted to transition probabilities. 
The assumption is that past distribution of the survival curves matched to the parametric 
curve will continue with the same distribution as the projected parametric curve.  
 
Similarly, AE distributions for the BEV plus the SOC arm were estimated using the real-
world SOC AE distributions and the AE’s relative risk from the clinical trials. As no 
patients in Ontario received the treatment, it was not possible to capture the true AE 
distribution for GBM patients on first-line therapy.  
 
From a QoL perspective, the study assumed a constant utility value during the 
progression free concurrent treatment phase, and a separate, albeit constant, utility value 
during the progression free maintenance phase. In the transition from concurrent to 
maintenance treatment, the treatment guidelines used indicate a several week 
chemotherapy treatment break. The absence of chemotherapy treatment can have either a 
positive or a possible negative effect on QoL; however, this possible change in utility has 
not been reflected in the analysis. Ideally, utility values could be established alongside 
treatment as observed in real-world practice to establish a longitudinal array of utility 
values, and therefore not have to make assumptions on utility increases or decreases over 
time and by health state. For practical purposes, this is not possible, and therefore in this 
analysis we assumed a constant utility during the progression free concurrent and 
progression free maintenance phase.  
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6.5. Conclusion 
This study evaluated the cost-effectiveness of BEV plus the SOC compared to the SOC 
for newly diagnosed GBM patients using Ontario health records, published RCT survival 
curves, and published utility analysis. In the base case scenario, BEV plus the SOC was 
found not to be more cost-effective than the SOC. The ICUR values for BEV plus the 
SOC is extremely high: $8,393,212 per QALY. The high ICUR was driven by high BEV 
costs and a very low incremental benefit. Deterministic sensitivity analysis found the 
ICUR is most sensitive to increased probability of remaining within the progression free 
survival state. Going forward, future research should focus on methods to increase the 
overall survival and progression free survival. As BEV has shown to have positive effects 
on progression free survival, the drug may have a place within the SOC if costs can be 
contained. This economic analysis will help decision makers guide policy into improving 
GBM patients’ lives, and improve the overall healthcare system.  
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Appendix 
 
Table 23. Patient Diagnosis Exclusion Codes 
OHIP Codes ICD-10 Codes 
Excluded if diagnosis within 12 month of treatment index date 
 I500 
Excluded if diagnosis within six month of treatment index date 
420, 428, 432, 435, 436 I64, I63, I62, I61, I60, I213, I212, I211, I210, I200, 
G45, B24, B23, B20, B22 
Excluded if diagnosis within 14 days of treatment index date 
280, 281, 282, 283, 284, 285, 
287, 288, 401, 402, 403, 410, 
413, 571, 573, 584, 585 
P610, N19, N18, N17, K778, K770, K77, K769, K768, 
K767, K766, K765, K764, K763, K762, K761, K760, 
K76, K759, K758, K754, K753, K752, K751, K750, 
K75, K746, K745, K744, K743, K742, K741, K740, 
K74, K739, K738, K732, K731, K730, K73, K729, 
K721, K720, K72, K719, K718, K717, K716, K715, 
K714, K713, K712, K711, K710, K71, K709, K704, 
K703, K702, K701, K700, K70, I21, I20, I15, I13, I12, 
I11, I10, D70, D696, D695, D694, D693, D693, D64, 
D63, D62, D61, D60, D59, D58, D57, D56, D55, D53, 
D52, D51, D50, M311, D696, D695, D695, D694, 
D593, D65 
Excluded if diagnosis within seven days of treatment index date 
286, 427, 441, 496 R17, J44, I72, I71, I49, I48, I47, D68, D67, D65, D66 
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Table 24. Procedure and Diagnosis Cost Codes 
Group OHIP Codes ICD 10 Codes Procedure Codes 
Protocol costs 
Excision   1AA87, 
1AB87,1AC87, 
1AE87, 1AF87, 
1AG87, 1AJ87, 
1AK87, 1AN87 
Pharmacotherapy   1AA35, 1AB35, 
1AE35, 1AN35, 
1ZZ35 
Radiation   1AC27, 1AE27 
Biopsy   2AA71, 2AC71, 
2AE71, 2AF71, 
2AG71, 2AJ71, 
2AK71, 2AN71 
Adverse event costs 
Abscesses fistulae 285, 284, 283, 282, 
280, 281 
  
Anemia  R430, P612, D649, 
D64, D630, D63, 
D62, D61, D60, D59, 
D58, D57, D56, D55, 
D539, D53, D52, 
D50, D51 
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Table 25 Continued. Procedure and Diagnosis Cost Codes 
Group OHIP Codes ICD 10 Codes Procedure Codes 
Arterial 
thromboembolism 
 I26, I74  
Bleeding 627, 569, 626 R58, R31, R048, 
R042, P26, N950, 
N938, N930, N93, 
N923, N92, N02, 
K922, K920, K5520, 
I859, I850 
 
Cerebral 
hemorrhage 
 S069, S068, S067, 
S066, S065, S064, 
S063, S062, P101, 
I62, I61, I60 
 
Congestive heart 
failure 
428 I500  
Fatigue 795 T676, R53, G933, 
M484 
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Table 26 Continued. Procedure and Diagnosis Cost Codes 
Group OHIP Codes ICD 10 Codes Procedure Codes 
Gastrointestinal 
perforation 
 T818, N82, N640, 
N360, N321, M251, 
K316, K114, J950, 
J860, I772, I770, 
I671, I280, I254, 
H831, H701, H046, 
N321, K833, K823, 
K632, K60, K316, 
K383 
 
 
Hemorrhage 666, 640, 532, 531, 
287, 432 
S064, R58, R31, 
R048, R042, P26, 
N938, N93, N92, 
N02, K922, K920, 
I62, I619, I618, I61, 
I608, I60, H431, 
H113, H356 
 
 
Hypertension 437, 403, 402, 362, 
401' 
P292, O16, K766, 
I959, I958, I95, I159, 
I1581, I158, I152, 
I151, I150, I15, I139, 
I132, I131, I13, I129, 
I120, I12, I119, I11, 
I101, I10, I100 
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Table 27 Continued. Procedure and Diagnosis Cost Codes 
Group OHIP Codes ICD 10 Codes Procedure Codes 
Leukopenia 288 C959, D70  
Lymphopenia 288 D728  
Mucocutaneous 
bleeding  
627, 569, 626, 666, 
640, 532, 531, 287, 
432, 627, 569, 626, 
786 
R042, R58  
Nausea and 
vomiting 
 R118, R11, R113  
Neutropenia 288 P615, D70, D700  
Proteinuria 791 R80, O122, O12103, 
O121, N391, N392 
 
Thrombocytopenia 287 P610, 'M311, D696, 
D695, D694, D6938, 
D693, D593, D65 
 
Thromboembolic 
disease 
452, 451 I82, I81, I26, I80, I74  
Venous 
thromboembolic 
452, 451 I82, I80, I81  
Visceral perforation 569 K631, S369  
Wound dehiscence 998 S061, T813  
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Table 28 Continued. Procedure and Diagnosis Cost Codes 
Group OHIP Codes ICD 10 Codes Procedure Codes 
Wound healing 
complications 
998 T813, T018, S061, 
T010 
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Figure 27. Full TreeAge model with all variables listed 
 
A. Economic Evaluation 
Economic evaluation is a mathematical framework integrating outcomes, risks, and costs 
of a medical or public health intervention [132]. The goal is to develop a method to 
holistically compare two or more options and choose the best one, however “best” is 
defined [113, 132, 133]. Healthcare resources are limited, and therefore efficiency usually 
defines the best option [132]. Outcomes and risks can be thought of as the clinical 
component of the framework, while costs represent the resource. Most interventions 
produce a benefit at some cost. The economic evaluation framework provides a method 
to compare the interventions. The framework is composed of two elements: interventions 
and health states. Interventions can be screening tests, treatments, or preventative 
measures: any action that can be deemed as a choice [133]. Health states are discrete 
conditions a patient can experience along the path from sickness to either health or death 
[133].  
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For example, a patient afflicted with a hypothetical illness can be presented with the 
following options: medication or no medication. These options represent the available 
interventions for the illness. By choosing an option, a patient can progress from several 
health states such as sick to healthy. As the patient passes through the health states, costs 
are incurred as are clinical outcomes: survival QoL. Economic evaluation brings together 
all components of the journey to compare the two interventions [113].  
 
A.1.1. Cost-Consequence Analysis 
Cost-consequence analysis is the simplest form of comparing two or more interventions. 
All the information for each intervention would be listed, and the evaluator would be left 
to synthesize and determine the best option [113].  
 
A.1.2. Cost-Minimization Analysis 
Cost-minimization analysis takes the information gathered and listed by a cost-
consequence analysis and calculates the difference in cost between a base options and 
various alternatives [113]. The implicit assumption is that the benefit of each option are 
equivalent or unimportant [113]. This type of analysis provides further structure 
compared to a cost-consequence analysis so that an evaluator can make an informed 
decision. 
 
A.1.3. Cost-Effectiveness Analysis 
Once the differential in costs is calculated between two interventions, the next step would 
be to incorporate the differing benefits from each intervention. The cost-effectiveness 
analysis requires the calculation of a ratio between the differential in costs divided by the 
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differential in benefit or effectiveness. The ratio is termed the incremental cost-
effectiveness ratio (ICER) and is listed in Equation 4. 
 
Equation 4. Formula used to calculate the incremental cost-effectiveness ratio (ICER) 
𝐼𝐶𝐸𝑅 =
𝐶𝑜𝑠𝑡𝐵−𝐶𝑜𝑠𝑡𝐴
𝐸𝑓𝑓𝑒𝑐𝑡𝐵−𝐸𝑓𝑓𝑒𝑐𝑡𝐴
=
∆𝐶𝑜𝑠𝑡
∆𝐸𝑓𝑓𝑒𝑐𝑡
         (4) 
 
As the costs of intervention B increases, the numerator increases. Therefore, the ratio 
increases in absolute value. If, however, the more expensive intervention B provides 
several more time the benefit than intervention A, the ratio can decrease in absolute 
value. Therefore, the ICER is dependent on both the additional costs and benefits of an 
alternative intervention. The willingness to pay is the maximum dollar per effect a payer 
is willing to pay per unit of benefit (e.g. per life year (LY) or quality adjusted life year 
(QALY)). If the ICER is higher than the willingness to pay, that is the incremental cost 
per incremental benefit is more than the maximum cost someone is willing to pay for the 
additional benefit, the new intervention can be rejected [113, 134].  
 
A.1.4. Cost-Utility Analysis 
The cost-utility analysis takes a simple concept of QoL and incorporates it into the ICER, 
termed the ICUR. Imagine that a patient’s QoL can be measured between the bounds of 0 
and 1, where 0 is no QoL and 1 is full QoL. The effect of an intervention can therefore be 
seen as how long a patient lives and the QoL during that life. The denominator can 
therefore incorporate the preference of a short life but high QoL intervention, compared 
to a long life, by poor QoL intervention [113]. As one can imagine, QoL can be very 
difficult to measure and preference can be dependent of the patient receiving the 
treatment.  
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A.1.5. Willingness to Pay 
Once the incremental cost-benefit ratio is calculated between the two interventions, a 
decision on whether the new intervention is beneficial over the base intervention. A cost-
effectiveness plane typically is used to explain illustratively the cost-benefit of a new 
intervention over the standard of case located at the x-axis and y-axis intercept (Figure 
28). 
 
   
 
 
Figure 28. Cost-effectiveness plane with the willingness to pay line and four quadrants 
 
The x-axis represents the incremental cost of the new intervention compared to the 
standard of care – it is the numerator of the ICER. The y-axis is the incremental benefit of 
the new intervention compared to the SOC – it is the denominator of the ICER. 
Therefore, if the ICER is positive, either the numerator and denominator are positive, or 
both are negative. Similarly, if the ICER is negative, either the numerator or denominator 
is negative. These four scenarios can be outlined as plot in one of the four quadrants in 
the cost-effectiveness plane.  
 
The base scenario is plotted at the x-axis and y-axis intercept. If the new intervention has 
a higher benefit, but lower cost, it has a negative ICER and is plotted in quadrant A. This 
scenario would be ideal, with a better outcome with lower costs, and would be accepted 
as cost-effective. If the new intervention has a higher benefit and a higher cost, it would 
be plotted in quadrant B. If the new intervention has a higher cost and lower incremental 
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benefit, it would be plotted in quadrant C, while a new intervention with a lower cost and 
lower benefit would be plotted in quadrant D.  
 
While a decision to accept a new intervention with an incremental cost/benefit in either 
quadrant A or C can be easily made, interventions in quadrant B and D are more difficult. 
A quadrant B new intervention implicitly states that at a higher cost, a better outcome is 
possible. However, financial resources are limited and therefore a decision needs to be 
made to decide how much benefit is required for each incremental dollar. The WTP is 
used to illustrate how much cost can be bore for each additional benefit. An intervention 
above the WTP line will provide more benefit per dollar than an intervention below the 
line. The slope of the line differs by country and by treatment area, but the WHO 
recommends a WTP line of one to three times the gross domestic product per capita 
(GDPC) per benefit [135]. Therefore, a new intervention above the WTP line can be said 
to provide enough benefit to justify the cost, while a new intervention below the line 
cannot. This study will use a WTP threshold of three times the 2014 GDPC as reported 
by the World Bank: $132,264 [98]. 
 
B. Decision Analytic Modelling 
To calculate the total costs and effects of each intervention, several mathematical 
methods can be used. Broadly, there is cohort based modeling and patient level modeling. 
Cohort modeling looks at the costs incurred by a population as they progress through the 
health states, while patient level modeling looks at the costs incurred by a patient as they 
progress through the health states. Thousands of patient journeys can be simulated, 
incorporating various patient characteristics, comorbidities, and event probabilities, to 
calculate the overall costs and effects of each intervention. Moreover, patient level 
modeling incorporates “memory” into the model so that future event probabilities can be 
dependent on prior events [113]. 
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Once a cohort or patient level based model is chosen, an analytical framework to evaluate 
the overall costs and effectiveness of each evaluated intervention must be chosen. 
 
B.1.1. Decision Tree Model 
A decision tree model calculates the expected costs and outcomes of an intervention, 
given event probabilities and costs. A decision tree is typically used when an intervention 
is a one-time event, such as surgery, and the procedure is evaluated over a set period of 
time [108]. There are three principal components to a decision tree model: 
 The square decision node – represents a decision between the two or more 
compared interventions.  
 The circle probability node – represents the probability that a patient will be in a 
particular health state, such as survival and death. 
 The triangle expected value node – represents the end of a scenario into a health 
state. The incurred costs and benefits are calculated until this point.  
The decision tree models a series of consequences, using event probabilities, based on a 
past decision. The final calculation a decision tree provides the expected value for each 
possible decision. For example, choosing intervention A versus intervention B may 
change the probability of a patient surviving an illness. The expected cost per benefit for 
intervention A and intervention B to make a decision can then be calculated. However, a 
decision tree is not adept at modeling recursive events and incorporating time into the 
model; instead, a decision tree will calculate the expected value for a disease within a 
period. Overall, decision trees are best at modeling treatment of an acute disease or one-
time event within a specified period [136].  
 
B.1.2. Markov Model 
Markov models build onto decision tree models by incorporating a time or cycle 
component. A Markov model is typically used when an intervention has a time 
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component, like treating cancer. While a several decision trees can be used to incorporate 
time, like a Markov model, at a certain point the decision tree model will become 
unwieldly and difficult to follow [108]. Markov models are recursive decision trees that 
track the probability a patient is in a finite number of possible health states at a given 
time. The probabilities that a patient will move from one health state to another, called 
transition probabilities, are then used to calculate the distribution of patients in each 
health state for the next time period. This gives Markov models the advantage over 
decision tree analysis to accurately discount expected values and track disease 
progression through its various states at any period. Markov models are therefore best 
suited to model chronic disease or disease progression that is time dependent. Advanced 
Markov models have the ability to incorporate the length of time a patient is within a 
health state and attributes the correct transition probability to that patient indicating that 
the probability of changing states is dependent on how long one was in that state on other 
time based factors [108].  
 
There are two components to a Markov model: 
 Cycles – Cycles refer to the number of fixed periods that an intervention is being 
evaluated. At the end of a cycle, a patient can remain in the health state they 
started the cycle in or change health states.  
 Transition probabilities – Transition probabilities refer to the probability that a 
patient will remain in a health state by the end of the cycle period. If a patient has 
a theoretical 50% chance of surviving a health state within a cycle, and 100 
patients are in that health state, then by the end of the first cycle 50 patients will 
have survived. By the end of the second cycle, 25 patients will have survived, etc. 
 
B.1.3. Microsimulation Model 
Microsimulation models build upon the Markov model, but allow for variability around 
the transition probabilities, costs, and benefits [113]. That is to say, we would expect that 
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on average a patient would remain in a state; however, some patients would remain in 
that state for longer and shorter periods. By analyzing the paths a simulated group of 
patients transition through, not only can the expected cost and benefit of an intervention 
be evaluated, but so can the variability [108, 113]. 
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